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Pulmonary Delivery of Brittle Matrix Powders Produced by Thin 
Film Freezing 
Yi-Bo Wang, Ph.D 
The University of Texas at Austin, 2013 
 
Supervisor: Robert O. Williams III 
 
Recently, the portfolio of compounds approved for inhalation therapy has expanded 
rapidly for lung disease therapies. The rationale for this delivery approach includes a 
more targeted and localized delivery to the diseased site with reduced systemic exposure, 
potentially leading to decreased adverse side effects. We have proposed that brittle matrix 
powders prepared by thin film freezing (TFF) are a suitable platform for pulmonary drug 
delivery which can achieve high lung concentrations while limit the corresponding 
systemic levels associated with toxicity, and enhanced physicochemical and aerodynamic 
properties can be obtained by varying TFF processing parameters. 
In Chapter 2, the in vitro and in vivo performance of an amorphous formulation 
prepared by TFF and a crystalline micronized formulation produced by milling was 
compared for Tacrolimus (TAC). TFF processed matrix powders was capable of 
achieving deep lung delivery due to its low density, highly porous and brittle 
characteristics. When emitted from a Miat® monodose inhaler, TFF processed TAC 
formulations exhibited a fine particle fraction (FPF) of 83.3% and a mass median 
ix 
 
aerodynamic diameter (MMAD) of 2.26 µm. Single dose 24-h pharmacokinetic studies in 
rats demonstrated that the TAC formulation prepared by TFF exhibited higher pulmonary 
bioavailability with a prolonged retention time in the lung, possibly due to decreased 
clearance (e.g., macrophage phagocytosis), compared to the micronized TAC formulation. 
Additionally, TFF formulation generated a lower systemic TAC concentration with 
smaller variability than the micronized formulation following inhalation, potentially 
leading to reduced side effects related to the drug in systemic circulation. 
Chapter 3 investigated the impact of processing parameters in the TFF process on the 
physicochemical and aerodynamic properties of the resulting formulations. All of these 
enhanced powder properties resulted from higher freezing rate contributed to a better 
aerodynamic performance of the obtaining formulations. Moreover, a decreasing trend of 
FPF was observed for these TFF powders when the initial solid concentrations increased. 
The variation of the freezing rate and initial solid loading in the TFF process enabled the 
production of formulations with enhanced physicochemical properties and improved 
aerodynamic performance. 
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Chapter 1 : The Impact of Pulmonary Diseases on the Fate of Inhaled 
Medicines 
 
1.1 Abstract  
The portfolio of compounds approved for inhalation therapy has expanded rapidly 
for treatment of lung diseases. To assess the efficacy and safety of inhaled medicines, a 
better understanding of their fate in the lungs is essential; especially in diseased lungs 
where a change in anatomical structure, ventilation parameters and breathing pattern may 
occur. In this article, the impact of lung pathophysiology factors on the fate of inhaled 
medicines is reviewed, and discussed in the context of aerosol deposition, dissolution, 
absorption and clearance. Special emphasis is given to computational modeling of aerosol 
deposition and clearance taking disease factors into consideration. In silico modeling can 
be used as a valuable tool to characterize the biopharmaceutics and pharmacodynamics of 
inhaled medicines, or assess risks associated with inhaled environmental pollutants for 
patients with pulmonary diseases. The deposition pattern of aerosol particles is greatly 
altered by different lung diseases based on both experimental data and model simulation. 
The fate of inhaled medicines after deposition primarily depends on the site of aerosol 
deposition. Therefore, when developing inhalation products for treatment of lung diseases, 
the dosing regimen, safety and pharmacokinetic studies should be conducted on patients 
with lung diseases, in addition to healthy subjects. 
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1.2 Introduction 
Treatment of lung diseases by drug inhalation has a long history beginning in the 
early 1950s when the first inhaled drug for asthma therapy emerged. Over the past 60 
years, significant inhalation products have been developed not only for the treatment of 
asthma, but also for other pulmonary diseases, such as chronic obstruction pulmonary 
diseases (COPD), cystic fibrosis, pneumonia, to name a few. The rationale for such 
treatments includes more localized and targeted delivery with minimum systemic 
exposure. More recently, systemic delivery of drugs administered by inhalation has 
gained attention due to advantages including: 1) enormous surface area of the lungs; 2) 
good epithelial permeability; 3) extensive vascularization; 4) faster onset of action 
compared to the oral route; 5) avoidance of first pass metabolism (Patton and Byron, 
2007). Therefore, a variety of inhalation products are under development for treatment of 
systemic diseases.  
Table 1.1 briefly summarizes the current inhalation products on the market or 
undergoing clinical studies, their drug classification and therapeutic usage. As listed in 
this table, majority of the inhalation products available on the market are locally acting 
drugs for treatment of lung diseases. These drugs are delivered to the lungs to either 
relieve the airway constriction or reduce inflammation and infection, which are mainly 
bronchodilators, corticosteroids and antibiotics. Most of the inhaled products designed to 
exert a systemic effect are still in clinical development, including fast-onset analgesics, 
peptides and proteins. Despite the rapid development of inhaled drugs for systemic 
3 
 
delivery, the inhalation market is still dominated by products for treatment of lung 
diseases.  
Understanding the fate of inhaled drugs in the lungs is essential for determining the 
therapeutic efficacy of inhaled pharmaceuticals for treatment of lung diseases. Recently 
published reviews have categorized the fate of inhaled medicines in healthy lungs into 
four processes, including deposition, dissolution, absorption and clearance.(Forbes et al., 
2011; Niven, 2011; Olsson et al., 2011; Todoroff and Vanbever, 2011; Yang et al., 2008b; 
Zhang et al., 2011). However, none of these reviews have considered the impact of 
diseased lung pathophysiology on each of these processes in the respiratory tract. A series 
of questions were posed by Patton et al. regarding how lung diseases affect the 
biopharmaceutics and pharmacodynamics of inhaled medicines (Patton et al., 2010). Still 
remarkably little is known in this field. If such questions are addressed, the pace of 
development of therapeutics for treating lung diseases may be accelerated. This review 
focuses on the fate of inhaled drugs in the lungs and the impact of lung pathophysiology 
on their fate. Aerosol drug deposition, dissolution, absorption and clearance are discussed 
in terms of how each process is influenced by pulmonary diseases. Computational 
modeling of aerosol deposition and clearance is discussed in detail as a powerful tool to 
predict the therapeutic efficacy of inhaled pharmacological drugs and risks associated 
with inhaled environmental aerosols.  
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1.3 Lung physiology and pathophysiology 
The lungs are composed of a series of branching airways, which can be classified 
into two parts: the conducting zone and the respiratory zone, as described by Weibel’s 
airway model (Fig.1.1) (Weibel, 1963). The conducting zone (generations 0 to 16) 
comprises of the trachea,  bronchi, bronchioles and terminal bronchioles, which are 
responsible for conducting air to the respiratory regions of the lung (Weibel, 1963). There 
are no alveoli in the conducting zone and the walls are too thick for diffusion; 
accordingly, no gas exchange occurs in this region (West, 2007). The total volume of the 
conducting zone is about 150 mL for a healthy human, and is also referred as the 
anatomic dead space (West, 2007). The terminal bronchioles branch into respiratory 
bronchioles, which have alveoli occasionally embedded within their walls. The 
respiratory bronchioles continuously branch into alveolar ducts and alveolar sacs, which 
are completely covered by alveoli. The respiratory bronchioles, alveolar ducts and 
alveolar sacs constitute the respiratory zone (generations 17 to 23), which facilitates gas 
exchange between airspaces and blood capillaries (Weibel, 1963). The length of the 
respiratory zone is only a few millimeters, but it composes most of the lung with a total 
volume of 2.5 to 3 L (West, 2007).  
Different types of epithelium line in different regions of the lung (Fig.1.2). In human 
bronchi, epithelia are composed of columnar basal, ciliated, brush and goblet cells (about 
60 µm in height) (Patton and Byron, 2007). There is a surface gel-aqueous layer lined on 
top of the cells. This layer is composed of a luminal mucus layer (consisting of 95% 
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water, 2% mucin, polymer, salts, proteins, and lipids), and a periciliary layer underlying 
the mucus layer with low viscosity to facilitate the cilia beating (Yang et al., 2008b). The 
coordinate beating of the cilia and the expiratory airflow transport the mucus towards the 
mouth to clear dust, microorganisms and insoluble particles out of the lungs, and this is 
referred as mucociliary clearance (Todoroff and Vanbever, 2011). The movement speed 
of mucus varies in different regions of the airways. It can go up to 20 mm/min in trachea 
and as slow as 1 mm/min in small peripheral airways (Olsson et al., 2011). When 
reaching the bronchioles and terminal bronchioles, the same types of cells are present on 
the epithelium but they are relatively small (around 10 µm in height). The complex gel-
aqueous layer lines the entire conducting airways and becomes progressively thinner 
from the trachea (up to 100 µm) to the bronchi (around 8 µm), and then to terminal 
bronchioles (about 3 µm) (Patton and Byron, 2007; Ungaro et al., 2012). In the alveolar 
region, the gel-aqueous layer is replaced by a thin liquid layer (<0.1 µm), which is 
composed of a pulmonary surfactant film and an aqueous subphase. The pulmonary 
surfactant consists of 80% phospholipids, 5-10% proteins and 5-10% other lipids (Ungaro 
et al., 2012). The tall columnar epithelial cells are replaced by thin and broad alveolar 
type I cells and alveolar type II cells (< 0.1 µm). Alveolar type I cells constitute more 
than 95% of the alveolar surface, which are adapted for gas exchange and prevent of fluid 
from entering into the alveoli. Alveolar type II cells are capable of generating into 
alveolar type I cells and producing surfactants, which allow alveoli to remain inflated at 
low distending pressures by decreasing surface tension and work of breathing (Todoroff 
and Vanbever, 2011). Another type of cell that exists in the alveolar region is the alveolar 
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macrophage. There is no mucus present in the alveolar region implying that mucociliary 
clearance is not active; therefore the main clearance mechanism in the alveoli is 
macrophage phagocytosis. Alveolar macrophages reside in the lung lining fluid beneath 
the surfactant layer (Todoroff and Vanbever, 2011). There are 12-14 macrophages in 
each of the 500 million alveoli in human lungs, and they only take up 1% of the alveolar 
surface (Geiser, 2010; Patton and Byron, 2007). However, they are capable of clearing all 
indigestible particles from the entire surface of the alveoli due to their amoeboid motion 
(Geiser, 2010).  
To better understand the fate of inhaled drugs, adequate knowledge of the movement 
of blood throughout the lung is critical as well. The blood supplied to the lung can be 
divided into two portions.  The pulmonary arteries carry unoxygenated blood from the 
right ventricle and branch successively paralleling the bronchi until reaching the terminal 
bronchioles. In the alveolar region, they branch into capillaries and form a network that 
covers the alveolar surface to facilitate the diffusion of both oxygen and carbon dioxide. 
Alveoli are completely enveloped in pulmonary capillaries and the dense network of 
capillaries provides an excellent environment for gas exchange. The blood-gas barrier 
between the capillaries and alveoli is extremely thin, with an average thickness of 0.2 to 
0.3 µm and a total area of 50-100 m
2
 (West, 2007).  Beyond that, freshly oxygenated 
blood from the capillaries goes into small pulmonary veins and eventually drains into the 
large vein that drains into the left atrium. Also, there is a small portion of systemic blood 
(via the bronchial circulation) that provides oxygen and nutrients to the larger airways 
bypassing the pulmonary capillaries. The bronchial circulation thus contributes a small 
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amount of unoxygenated blood (called venous admixture) to the left ventricle and the 
systemic circulation.  Lymphatic vessels (which drain fluid from the pleural surface and 
the interstitium) accompany major blood vessels and airways in the lung as well (El-
Chemaly et al., 2009).  
Lung diseases are some of the most common medical conditions around the world 
(West, 2012). There are lung diseases predominately affecting the airways (e.g. asthma, 
COPD, cystic fibrosis), diseases affecting the alveoli (e.g. pneumonia, pulmonary edema, 
lung cancers) and diseases affecting the surrounding blood vessels and intersitium(e.g. 
pulmonary embolus, pulmonary hypertension, interstial lung disease) (West, 2012). 
However, many of these diseases affect more than one compartment of the lung. Table 
1.2 summarizes the most commonly occurring lung diseases, their definitions, causes, 
symptoms and pathophysiology. As mentioned before, very little is known about the 
impact of lung diseases on the fate of inhaled medicines (Patton et al., 2010). Now, the 
biopharmaceutics and pharmacokinetics of inhaled drugs in the lungs affected by 
pathophysiological factors of different lung diseases are discussed for each process: 
deposition, dissolution, absorption and clearance.  
1.4 Drug deposition altered by lung diseases 
1.4.1 Present State of Art 
The site of aerosol deposition in the respiratory tract is critical when determining the 
fate of inhaled medicines. Numerous reviews and studies have discussed the basic 
mechanisms of aerosol deposition in the lung, the size of particles that can be optimally 
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deposited in the lung, and the factors that affect the deposition efficacy (Patton and Byron, 
2007; Rogueda and Traini, 2007; Todoroff and Vanbever, 2011; Yang et al., 2008b). The 
site of aerosol deposition is determined by the aerodynamic diameter of the aerosol 
particles. In the oropharynx and large airways (including the trachea and bronchi) where 
the air velocity is relatively high, large particles (>5 μm) are deposited by inertial 
impaction because they are unable to follow the change of airstream flow direction. 
Smaller particles (1–5 μm) are capable of traveling through the upper regions of the lung 
and deposited in the bronchioles by gravitational sedimentation, where the air velocity is 
low. In the terminal bronchioles and alveolar region where air velocity is negligible, 
particles (<0.5 μm) are deposited mainly by diffusion.  
In general, two distinct particle size ranges for enhancing alveolar deposition are 1-3 
µm (Byron, 1986) and <100 nm (Crampton et al., 2004). The latter size range is rarely 
used in developing inhalation products partially because it’s difficult to generate stable 
aerosol particles in the range of 50-100 nm (Rogueda and Traini, 2007). It has also been 
reported that aerosol particles with aerodynamic diameter less than 1 µm can be exhaled 
up to 80% without deposition due to their low inertial (Heyder et al., 1986). However, 
aerosol particles deposition in the alveolar region is bi-model. Ultrafine particles (<100 
nm) tend to achieve high alveolar deposition fraction (up to 50%) (Yang et al., 2008b), 
and the deposition efficiency increases as the particle size decreases (Rogueda and Traini, 
2007). .  
9 
 
Aerodynamic diameter (Dae ) is defined as the diameter of a unit density (ρ0) sphere, 
which has the same terminal velocity in still air with the particle. Aerodynamic diameter 
can be calculated by the equation below: 
       √     ⁄  
Where Deq is the geometric diameter of the particle; ρ p is the particle density and Χ 
is the dynamic shape factor derivate from sphere. The dynamic shape factor equals 1.00 
for a spherical particle. When particle shape becomes irregular, the dynamic shape factor 
increases. For instance, the dynamic shape factor is 1.08 for a cube particle, 1.14 for 
cylinder, 1.57 for sand and 1.88 for Talc (Scheuch and Heyder, 1990). According to the 
above equation, optimum aerodynamic diameter can also be achieved by generating 
particles with relatively large geometric size but low particle density or high particle 
irregularity. Edwards reported use of large porous low density particles to achieve 
excellent aerodynamic properties (Edwards et al., 1997).  Since then, numerical 
technologies have been proposed to enhance the aerodynamic performance of dry powder 
formulations (Duddu et al., 2002; Plumley et al., 2009; Richardson and Boss, 2007; 
Tomashefski Jr. et al., 1993; Vanbever et al., 1999; Watts et al., 2013). As summarized in 
Table 1.3, the respirable fractions of DPIs prepared by these technologies are 
significantly higher than that of traditional carrier-based DPIs (10-35%) (Crowder et al., 
2002). Besides aerodynamic diameter, the site of aerosol deposition in the respiratory 
tract is also affected by the anatomy of the airway, breathing pattern, flow rate and tidal 
volume of the patients (Byron and Patton, 1994).     
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Godleski group has conducted a series of studies on how different lung diseases 
altered the aerosol deposition pattern in animal models (Brain et al., 1984; Sweeney et al., 
1983; Sweeney et al., 1987; Sweeney et al., 1995). Among all these studies, Insoluble 
99m
Tc-labeled aerosol particles were utilized to trace the aerosol deposition pattern. 
Autoradiography imaging was captured on the excised pieces of lung to evaluate aerosol 
deposition uniformity. A new parameter was introduced in these studies, the Evenness 
Index (EI), which was calculated by the radioactivity of each individual sample of lung 
divided by the radioactivity of the entire lung. If the aerosol is uniformly deposited in the 
whole lungs, the EI would be 1.0 with a Standard Deviation (SD) equal to 0. An EI<1.0 
means the sample has less aerosol deposition than the average; to the contrary, an EI>1.0 
means that sample receives more than average. Smaller SD indicates that aerosols are 
more homogenously deposited in the lungs. Rat model with chronic bronchitis (CB) was 
induced by exposure to sulfur dioxide (SO2). The control group rats had a more 
homogenous deposition pattern (SD=0.27) than the CB group rats (SD=0.49). 
Additionally, CB rats exhibited an enhanced large airway deposition compared with 
healthy rats because reduction of airway diameter in CB rats may cause increased inertial 
impaction efficiency in the large airways (Sweeney et al., 1995).  
Another lung disease, emphysema was introduced to hamsters by intratracheal 
elastase installation. Similar to the CB rats, the hamsters with emphysema exhibited less 
uniform deposition and an enhanced large airway deposition compared to healthy 
hamsters (Sweeney et al., 1987). Godleski group also studied pulmonary fibrosis, which 
was induced by a combination of intratracheal bleomycin and O2 to hamsters. Hamsters 
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with fibrosis received 60% less particles than the control hamsters in the whole lungs 
with more heterogeneous distribution. No difference was observed among the diseased 
group and the control group in terms of breathing pattern, indicating the aerosol 
deposition pattern was altered primarily by the anatomical change of the airways rather 
than the breathing pattern.  
The difference of particles distribution in these three types of diseased lungs depends 
on the diseased lesions of the lung. For CB lungs, the diseased lesion is in the large 
airway not the parenchyma, so aerosol particles mainly deposited in the airway lesion 
causing large portions of the parenchyma lung have low deposition (Sweeney et al., 
1995). In emphysematous lungs, two diseased components may be attributed to the non-
uniform distribution of aerosol particles: changes in lung volumes and static pulmonary 
compliance; change in total pulmonary resistance associated with airways. The increased 
lung volume and reduced surface area due to destruction of terminal air spaces result in 
heterogeneous distribution of ventilation, airway closure and enhanced airway deposition 
(Sweeney et al., 1987). In fibrotic lungs, the diseased lesion primarily occurs in 
parenchyma rather than airways. The most diseased site retained the smallest amount of 
particles, because the fibrotic lesions affected the ventilation parameters and the available 
surface area for deposition (Brain et al., 1984; Sweeney et al., 1983). 
Similar radiographic technologies have been used in several clinical studies to 
investigate the impact of pulmonary disease on aerosol deposition in human lungs. The 
diseases have been studied include COPD (Brown et al., 2002; Kim and Kang, 1997), 
asthma (Kim and Kang, 1997), cystic fibrosis (Anderson et al., 1989; Anderson et al., 
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1990). As illustrated in Fig.1.3, aerosol particles tend to have higher and non-uniform 
deposition in the diseased lesions of patients with obstructed lungs compared to healthy 
subjects. Moreover, the enhancement of deposition efficacy at the diseased site increases 
with the severity of lung obstruction or lung dysfunction (Anderson et al., 1994; Brown et 
al., 2001; Itoh et al., 1981; Love and Muir, 1976; Siekmeier et al., 1990). Possible 
reasons responsible for the enhanced aerosol deposition in patients with obstructed lung 
diseases are as follows: an increase in upper airway inertial impaction attributed to the 
reduction of airway diameter resulting from constriction or thickening of mucus; non-
uniform ventilation distribution may cause particles to retain in the alveolar region for a 
longer time; enhanced flow turbulence at the site of obstruction which increases the 
chance for particle impaction with the airway walls.  
1.4.2 Modeling of aerosol deposition and associated lung diseases 
To reduce the cost associated with complex animal and clinical studies, 
mathematical modeling of aerosol deposition in the human respiratory tract has been used 
to predict deposition and distribution of inhaled pharmaceuticals. However, modeling of 
aerosol deposition requires a comprehensive knowledge of the geometry of the lungs, the 
fluid dynamic properties of particles in the airways and the supporting experimental data 
for model validation. The fundamental theory and airway morphology involved in aerosol 
deposition modeling, the current existing deposition models and factors affecting the 
deposition, experimental measurement for particle deposition and model validation was 
recently reviewed (Martonen et al., 2013).  
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A very popular analytical model used for simulation of the deposition and 
distribution of aerosols within the respiratory tract of the lung was proposed by Martonen 
(Martonen, 1982). Briefly, the human lung is considered as a dichotomous hierarchy of 
symmetrical tubes. The tracheobronchial airways (TB) are numbered from generation I=0 
to 16, and the pulmonary region (P) is numbered from generation I=17-23. P contains 
three generations of respiratory bronchioles containing some alveoli, three generations of 
alveolar ducts and alveolar sacs. The angles of bifurcation and gravity within the airways 
are 70° and 45°, respectively. Two identical sets of 20 airways are present in each 
generation. The morphology of the lung (Fig.1.4) is described by a supercomputer 
algorithm (Martonen et al., 1997). 
Particle deposition is a function of airway geometries, particle characteristics and 
breathing conditions. The three major deposition mechanisms have different 
mathematical expressions when different fluid dynamic patterns are applied to aerosol 
particles (Martonen et al., 1997). In this model, the entire airway is divided into the large 
airway (generation 0-4) with turbulence flow; central airway (generation 5-10) and small 
airway (generation 11-15) with laminar flow at instant rate; alveolar 5 compartment 
(generation 16-23) with laminar flow of parabolic velocity profile (Martonen et al., 2003). 
Particle deposition equations depending on different flow conditions and deposition 
mechanisms are presented in Table 1.4. The cumulative deposition at each generation 
P(C) can be calculated according to the following equation:  
 ( )   ( )   ( )   ( )   ( ) ( ) ( )   ( ) ( )   ( ) ( )   ( ) ( ) 
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Tremendous progress has been made in the field of multimodality imaging 
technologies in the last 20 years. Single Photon Emission Computed Tomography 
(SPECT) and Positron Emission Tomography (PET) are capable of providing more 
accurate three-dimensional data on aerosol deposition (Conway et al., 2013). The 
combination of high resolution computed tomography (HRCT) with data acquired from 
SPECT or PET provides deposition data more 15 related to anatomy of the lung (Fleming 
et al., 2011); in addition, HRCT enables the simulation of aerosol deposition based on 
individual patients rather than generic model (Conway et al., 2013). Therefore, more 
experimental data can be used for model validation. Moreover, as the advances in 
deposition modeling, more and more input parameters can be incorporated into the model. 
Table 1.5 summarizes the available input and output parameters for aerosol deposition 20 
modeling.  
     
In this article, we focus on discussing the incorporation of pulmonary disease factors 
into the aerosol deposition models. Segal et al. used a computer model to evaluate the 
particle deposition pattern within the lungs of COPD patients compared to healthy 
patients (Segal et al., 2002). The morphology of COPD lungs are modeled based on both 
chronic bronchitis (obstructed airways) and emphysema (degeneration of alveoli). 
Chronic bronchitis (CB) was modeled by reduction of airway diameters and emphysema 
was modeled by increasing alveolar volumes. For CB lungs, the airway generations 0-16 
are narrowed, so the aerosol particles travel in a higher velocity. Therefore, deposition by 
inertial impaction is remarkably enhanced in the TB region because it’s proportional to 
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the magnitude of the velocity. Moreover, deposition by sedimentation and diffusion is 
slightly increased. The particles pass through the TB relatively quickly due to accelerated 
velocity, and the inhalation time is fixed. Thus they tend to resident in the alveolar region 
for a longer time. Deposition by sedimentation and diffusion are dependent on residence 
time, hence an increased deposition in generations 17-23 is expected. For emphysema 
diseased lungs, aerosol deposition slightly decreases because particles must travel a 
longer distance to deposit on the airway walls due to the increase of alveolar volume.  
Martonen et al. simulated asthma based disease parameters on three pathophysiology 
factors of the human airways: bronchoconstriction of the smooth muscle, inflammation of 
the airway walls and thickening of the mucus layer (Martonen et al., 2003). The 
enhancement of aerosol deposition occurred primarily in the region where asthma is 
located (airway obstruction). Studies with human subjects using SPECT images to trace 
the aerosol deposition (MMAD=1.8 µm) in healthy and asthmatic groups were conducted 
to validate the model simulation. In the control group, aerosol particles were uniformly 
deposited throughout the entire lungs; in the asthmatic group, increased deposition in the 
central airway and deceased deposition in the peripheral airways were observed, which is 
correlated with the model simulation results. Another study of has confirmed that regions 
where bronchoconstriction occurred are the primary sites that the aerosol deposition is 
enhanced (Sbirlea-Apiou et al., 2004). This study also evaluated the impact of aerosol 
particle size and the breathing flow rate on enhancement of deposition efficacy. The 
results illustrated that the enhancement of deposition increased with increased particle 
size and higher flow rate due to more efficient inertial impaction. These findings might 
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be viewed as a benefit for site-specific acting drugs targeting the conducting airways 
(bronchodilators, anti-inflammatory agents, etc.). 
Cystic fibrosis (CF) is a genetic disease characterized by hypersecretion of highly 
viscous mucus, leading to obstructed airway, airway inflammation and infection. 
Regardless of the initial disease established sites, CF patients will eventually develop 
obstructive lung disease, which accounts for more than 90% of the death caused by CF 
(Tomashefski Jr. et al., 1993). The simulation of cystic fibrosis in a mathematical model 
is represented by reduction in airway diameter, due to thickening of the mucus layer, 
airway infection and inflammation, or a combination of the three factors. It is well known 
that in CF, mucous can eventually fill the airways resulting in complete airway 
obstruction. In studies conducted by Martonen et al., only partial blockage of airways was 
considered in the model and the term Airway Coefficient (AC) was used to describe the 
reduction in airway diameter (Martonen et al., 1995; Martonen et al., 1997). The severity 
of disease was considered in the model as well. AC=1.0 means normal airway without 
any disease; AC=0.8 represents 20% in diameter reduction; AC=0.6 indicates 40% in 
diameter reduction. Other parameters added to the model are the ventilation parameters. 
Table 1.6 gives the breathing pattern of adults at two conditions, sedentary and light 
activity. The simulated aerosol deposition results demonstrated that under the sedentary 
breathing condition, particle deposition primarily occurred in the alveolar region of the 
lung. Moreover, the enhancement of alveolar deposition increased with the severity of 
disease. The shift of aerosol deposition to the upper airways is more pronounced for 
larger particle sizes (4 µm) and the light activity breathing condition with high inspiratory 
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flow rate. The reason can be attributed to the enhanced deposition efficiency by inertial 
impaction. Therefore, the deposition of inhaled medicines is substantively altered by the 
degree of airway congestion (severity of disease), and this impact should be considered 
when designing inhalation therapy protocols with appropriate prescribed breathing 
regimens.   
Lung tumors affecting the airways have been simulated using computer models as 
well (Farkas and Balásházy, 2007; Martonen and Guan, 2001a, b). Lung carcinomas are 
classified into two types, sidewall and carinal tumors. For sidewall tumors, the deposition 
efficiency of large particles (micron-sized) was highly enhanced; on the other hand, 
nanoparticles tend to have lower deposition efficiency compared with healthy airways. 
For carinal tumors, enhanced deposition efficiency for micron-sized particles was found 
and the deposition of nanoparticles was barely affected by the presence of the tumors 
(Farkas and Balásházy, 2007). Similar to other airway obstructed diseases, the 
enhancement of aerosol deposition on the tumor sites increases with increasing of aerosol 
particle size, breathing intensity and tumor size (Martonen and Guan, 2001b).  
Aerosol particle deposition is enhanced for diseased lungs most of the time. However, 
pulmonary diseases may have a negative effect on breathing pattern, which can 
potentially impact the deposition of inhaled pharmaceuticals. Breathing pattern is 
typically described in the terms of tidal volume (volume of air inhaled) and flow rate. In 
general, higher lung deposition has been observed with larger tidal volume because 
particle-carrying air is capable of penetrating deeper into the lung. Particle deposition in 
the lung is enhanced with lower flow rate because when the air velocity is low particles 
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tend to have more time for sedimentation and diffusion (Kim and Hu, 2006; Martonen et 
al., 2013). Patients with impaired lung functions caused by different lung diseases 
(COPD, asthma, bronchiectasis etc.) may have very variable spontaneous breathing 
patterns (tidal volume ranging from 250-2000 mL, flow rate less than 200 to 1000 mL/s). 
Therefore, they tend to have a lower total lung deposition and greater intersubject and 
intrasubject variability compared to healthy subjects. When using a controlled slow 
breathing pattern, higher deposition fraction and smaller intersubject and intrasubject 
variability were achieved because more time are allowed for aerosol particle 
sedimentation and diffusion. Thus differences in deposition between healthy subjects and 
patients were negligible (Brand et al., 2000). A typical 8-10s breath holding after 
inhalation is recommended on clinical to enhance the deposition of aerosol medicines; 
however, apparently it’s often impossible for patients with severe lung diseases. 
Nevertheless, when prescribing aerosol medicines, a more slow and deep breathing 
pattern is recommended to attain the best performance of inhaled medicines, especially 
for breath-actuated pMDIs and DPIs (Ari et al., 2012). 
One of the most promising applications of computational modeling of aerosol 
deposition is to aid the designing of inhaled pharmaceuticals and the associated devices. 
In silico models are capable of predicting the optimized particle properties and proper 
breathing conditions for patients (e.g. velocities, breath holding time) to achieve targeted 
delivery of aerosols to the diseased lesions of the respiratory tract. Generally, when 
treating lung diseases, high aerosol deposition in the smooth muscle–lined airways of the 
lungs is preferred; for systemic applications, enhancing the aerosol deposition in the 
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pulmonary region (i.e. alveoli) is recommended (Martonen et al., 2013). Moreover, 
aerosol deposition models can also be used to interpret performance of different devices 
in clinical studies, such as nebulizers, pMDIs and DPIs (Zhang et al., 2007).          
Another application of aerosol deposition modeling is risk assessment of inhaled 
particulate matter. The U.S. Environmental Protection Agency (EPA) has recently 
approved several stochastic human exposure models for these purposes, including the Air 
Pollutants Exposure (APEX) model of EPA’s Office of Air Quality Planning(EPA., 
2008a), SHEDS-PM and Exposure Model for Individuals (EMI) of EPA’s Office of 
Research and Development (Burke et al., 2001; EPA.). The U.S. EPA office has 
identified persons suffering from respiratory disease as a sensitive population needing 
particular consideration in risk assessment of inhaled particulate matter and in the 
establishment of air pollution standards (Martonen et al., 2013). Therefore, more 
advanced models of particle deposition that can incorporate a variety of pulmonary 
diseases are desirable. 
In summary, in silico modeling of aerosol deposition and combination of pulmonary 
disease factors provide a valuable tool for predicting the distribution of therapeutic 
aerosol in the human respiratory tract. Additionally modeling assists in minimizing the 
cost of animal and clinical studies by aiding in reasonable design of experiments based on 
sound scientific hypothesis. Computational modeling is also capable of predicting the 
inhalation toxicity of air pollutant particles for patients with lung disease. As mentioned 
by Martonen et al., in silico modeling of aerosol deposition should be utilized in a 
complementary manner with aerosol therapy protocols (Martonen et al., 2013).  
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1.5 Drug absorption affected by lung diseases 
After deposition, aerosol particles will directly contact with the pulmonary epithelial 
lining fluid (ELF). The thickness and composition of the ELF are different at different 
regions of the respiratory tract. Hence, the fate of the deposited aerosol particles depends 
on the site of deposition, the aqueous solubility and the dosimetry. If the drug is freely 
soluble in water (e.g. albuterol sulphate, disodium cromoglycate, insulin, calcitonin and 
tobramycin), it will readily dissolve in the pulmonary lining fluid and be available for 
absorption or clearance (Patton et al., 2010; Zhang et al., 2011).  The pharmacokinetics 
(PK) behaviors of water-soluble drugs after inhalation of the powder form versus the 
liquid form have been reported to be similar in human subjects (Clark et al., 2008; 
Newhouse et al., 2003; Sakagami, 2004; Tolman and Williams, 2010). It indicated that 
dissolution kinetics may not be the rate-determining step for lung pharmacokinetics and 
pharmacodynamics following inhalation of water-soluble drugs. For poorly water-soluble 
drugs (e.g. budesonide, fluticasone and mometasone), the deposited dose may exceed the 
aqueous solubility due to the limited volume of pulmonary lining fluid (i.e., 10-30 mL in 
healthy human) (Patton et al., 2010). Consequently, the absorption rate is impacted by the 
dissolution controlled kinetics in the lung. Enhanced lung absorption using different 
formulation strategies, which are capable of improving the solubility of poorly water 
soluble drugs have been proposed recently (Dugas et al., 2013; Sinswat et al., 2008; Yang 
et al., 2008a; Yang et al., 2010).  
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Following dissolution, the absorption rate of the drug depends on the hydrophicility 
of the molecules. For small hydrophilic molecules, the absorption is relatively fast with a 
half-life of about one hour; for small hydrophobic molecules, the absorption is extremely 
fast, and the half-life is usually on the order of 1-2 minutes (Patton et al., 2004); the case 
is more complex for large molecules. Small peptides and proteins can be absorbed 
quickly but they are also metabolized at the same time.  Large proteins are more resistant 
to metabolism compared to small peptides and proteins, but the absorption is slower and 
the bioavailability is more variable (Patton et al., 2004). There are several mechanisms 
that facilitate absorption from the lung into the blood, lymph or cells. Passive diffusion is 
an important one. It has been reported that hydrophilic compounds tend to be absorbed 
via paracellular diffusion and intercellular junction pores while the absorption of 
hydrophobic compounds occurs through transcellular diffusion (Effros and Mason, 1983). 
Drug transporters also play an important role in pulmonary absorption. The drug carrier 
transporters may mediate drug uptake into cells and transfer across the cell membrane, 
especially for drugs with low passive permeability (Olsson et al., 2011). In addition, 
membrane vesicles and caveolae that are present in alveolar type I cells have been shown 
to be involved in drug transport across the alveolar epithelium (Crandall and Matthay, 
2001; Gumbleton, 2001).  
If the aerosol particles are not immediately dissolved in the pulmonary lining fluid, 
they might be able to transport across the airway and alveolar epithelial cells as intact 
particles. In the upper airways where the mucus layer acts as a physical barrier, the pore 
size available for particle transport is approximately 500 nm. Additionally the high 
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viscosity of mucus can trap the particles and subject them to mucociliary clearance 
(Dawson et al., 2003; Sanders et al., 2000). In the alveolar region, the thin layer of lining 
fluid and alveolar type I cells provides very little resistance to particle transport; hence 
particle transport across the epithelial layer is mostly enhanced in this region (Patton et 
al., 2010). The mechanism of particle transport across the epithelial cells is transcytosis, 
which can be mediated by protein-binding (Schmid et al., 2009) or receptor-mediated 
caveolae (available for particles in the size range 50-100 nm) (Crandall and Matthay, 
2001). 
Drug absorption depends on the site of aerosol deposition, and the deposition pattern 
is greatly altered by lung diseases; consequently drug absorption is influenced by 
pulmonary disease as well.  For obstructed airway diseases (e.g. asthma, COPD etc.), 
absorption of inhaled drugs is expected to be rendered due to the enhanced deposition in 
the diseased upper airways and potentially reduced surface area. Recently, the 
pharmacokinetic profile of a new long acting β2 agonist (PF-00610355) used for once 
daily treatment of COPD has been studied to characterize systemic exposure related to 
drug adverse effects. The results are summarized from 264 subjects enrolled in 8 studies, 
including healthy volunteers,  asthmatic and COPD patients(Diderichsen et al., 2013). As 
shown in Fig.1.5, the mean maximum concentration (Cmax) is reduced by 52% and 31% 
for asthma and COPD patients, respectively, compared to healthy volunteers following 
the first inhalation dose. The decreased systemic drug concentration for patients with 
asthma and COPD can be attributed to the reduced aerosol deposition in the alveoli, 
where systemic absorption is maximized (Fig.1.5). Another clinical study among healthy 
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and asthmatic patients was carried out to evaluate the insulin pharmacokinetics and 
pharmacodynamics following a single inhalation of AERx insulin system (Henry et al., 
2003). Inhaled insulin for healthy subjects displayed a significantly higher AUC and Cmax 
compared to asthmatic patients, indicating that less insulin was absorbed in asthmatic 
patients. A consistently reduced blood glucose level for healthy subjects was observed 
compare to asthmatic patients. In addition, the asthmatic patients exhibited greater 
intrasubject variation than the healthy subjects, because the non-uniform diseased lesions 
between asthmatic subjects resulted in more variable deposition.  
Similar reduction in systemic bioavailability was also observed in inhaled 
combination therapy of budesonide/formoterol and salmeterol/fluticasone for COPD 
patients versus healthy subjects (Dalby et al., 2009). One of the inhaled corticosteroids, 
fluticasone, has been shown to exhibit reduced systemic exposure in both asthmatic and 
COPD patients compared to health subjects (Falcoz et al., 2000; Singh et al., 2003). The 
mucus thickening of cystic fibrosis and chronic bronchitis may impede air-blood transfer 
of drug molecules or particles; thereby decreases systemic absorption and bioavailability 
of inhaled medicines (Geller et al., 2011; Lenney et al., 2011; Pilcer et al., 2008). 
Decreased systemic absorption of inhaled medicines in patients with obstructive lung 
diseases is beneficial for locally acting drugs; because it can achieve high drug exposure 
at the diseased sites and has the potential to lower adverse effects related to drug 
concentration in the systemic circulation. Therefore, the pharmacokinetics, safety-risk 
assessment and dose regimen determination should be conducted on patients with the 
relevant diseases in addition to healthy volunteers.  
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Other lung diseases may also have an impact on systemic absorption of inhaled 
pharmaceuticals. Emphysema, characterized by destruction of alveolar walls and 
consequent enlargement of air-spaces, will cause loss of functional surface area in the 
alveoli, and further results in decreased systemic drug absorption (West, 2012). 
Pulmonary fibrosis is a disease that is characterized by excess fibrous connective tissues 
in the lungs. As the severity increases, the diseased lesions become more heterogeneous. 
The reduction in vascular density and the increase in sclerotic conditions of the lung 
parenchyma will lead to a decrease of air-blood drug transfer; hence lower the systemic 
exposure of inhaled medicines (Patton et al., 2010). Pulmonary embolus is a lung disease 
that affects the blood vessels. The blood flow to one or more pulmonary arteries is 
obstructed by a thrombus, leading to decreased drug absorption into the systemic 
circulation. Pulmonary arterial hypertension (PAH) is another pulmonary vascular 
disease. In PAH, the pulmonary arteries constrict abnormally, leading to high pressures in 
the pulmonary vasculature and right ventricular dysfunction. Inhaled vasodilators (e.g. 
iloprost) have been shown to be an effective treatment for PAH. (Baker and Hockman, 
2005; Mulligan and Beghetti, 2012). Due to the constriction, high pressure within the 
pulmonary arteries and reduced cardiac output, the systemic exposure of inhaled 
medications will be reduced for PAH patients compared to healthy subjects.      
Inhalation therapies for lung cancer have been developed in animal models (Latimer 
et al., 2009) and human clinical trials (Wittgen et al., 2007). The rationale is attempting to 
achieve higher drug concentration at the disease sites and reduce systemic side effects. 
However, the impact of pulmonary tumors on drug absorption is not fully understood. 
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Lung tumors, for both sidewall and carinal tumors, will lead to obstructed or blockage of 
airways. Consequently, tumors will receive higher drug exposure when treated locally by 
inhaling anti-cancer agents. On the other hand, the systemic toxicity related to drug 
concentration will be reduced due to lower alveolar deposition. Therefore, treating 
tumors via the pulmonary route is a sound approach for lung cancer therapy.  
Chronic airway inflammation is typically associated with epithelial dysfunction, 
injury and enhanced epithelium permeability due to loss of barrier integrity (Bayram et 
al., 2002; Knight and Holgate, 2003). In models of allergic airway inflammation, it has 
been shown that epithelial barrier function and tight junction proteins are dysregulated 
(Cloutier et al., 2004; Evans et al., 2002). Various inflammatory mediators are 
responsible for this dysfunction (Bruewer et al., 2003; Coyne et al., 2002; Han et al., 
2003). Furthermore, the enhancement of epithelial permeability will accelerate 
paracellular transport of hydrophilic molecules. Permeability Edema (PE), is a major 
complication of severe pneumonia, acute respiratory distress syndrome and acute lung 
injury. PE will cause epithelial and endothelial barriers impairment and hyper 
permeability, which can further enhance the paracellular transport of hydrophilic 
molecules (Olsson et al., 2011). 
Caveolae mediated transcytosis across the epithelium is another important drug 
absorption mechanism in the lung that in response to lung pathophysiological factors. 
Transcytosis starts with the pitch off of caveolae from plasma membrane on either front 
of the cell; forms discrete vesicle by membrane fusion and moves to the opposite front of 
endothelial cells in the fluid phase bypass the lysosomes; then fuses with plasma 
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membrane and discharges the cargo content to the perivascular space (Predescu et al., 
2007). Caveolins are unique proteins in the caveolae. They are in charge of modulating 
cellular signaling and vesicular transport  by generating a scaffolding domain that 
sequesters receptors, ion channels, second messenger producing enzymes and effector 
kinases to the caveolae (Tiruppathi et al., 2008). There are numerous caveolae and high 
levels of caveolins expressed in the lung; therefore they are significantly involved in the 
airway epithelium, smooth muscle, fibroblasts, inflammatory cells and the pulmonary 
vasculature. It has been suggested that the caveolae-mediated transcytosis is greatly 
impacted by changes in cellular signaling associated with asthma, COPD, lung cancer, 
pulmonary fibrosis and pulmonary vascular diseases (Gosens et al., 2008).          
1.6 Pulmonary clearance influenced by lung diseases 
1.6.1 Mucociliary clearance and impact of lung diseases 
In the conducting airways (Fig.1.1, generation 0 to 16), mucociliary clearance (MCC) 
is the dominant defensive mechanism (Geiser and Kreyling, 2010). Mucus is secreted by 
mucous glands in the bronchial walls and by goblet cells in the bronchial epithelium 
(Martonen et al., 2013). The production rate of mucus is about 10-20 ml/day for a healthy 
human; in a patient with chronic bronchitis up to 10 times this volume may be produced 
per day (Toremalm, 1960). Beneath the mucus layer, there are millions of cilia with their 
tips reaching into the mucus and the coordinated beating of the cilia facilitates the 
moving of mucus towards the larynx/pharynx. Insoluble particles trapped in the mucus 
will be transported along with the mucus to the upper airway and swallowed (Fig.1.6) 
27 
 
(Antunes and Cohen, 2007). The velocity of mucus moving upwards varies at different 
regions of the airway, and it is reported to be as slow as 1 mm/min in small peripheral 
airways and up to 20 mm/min in the trachea (Olsson et al., 2011; Yeates et al., 1981).  
Insoluble particles deposited in the airways having a geometric size larger than 6 µm 
are preferably cleared by MCC (Stahlhofen and Scheuch, 1990). Smaller particles 
deposited in the upper airways tend to penetrate the mucus layer, and are taken up by 
epithelial cells; thereby escaping from MCC (Kreyling et al., 2006). Once trapped in the 
mucus layer, the clearance rate of aerosol particles by MCC is independent of size, shape, 
charge and surface properties. Additionally the vertical penetration rate of trapped 
particles toward the epithelium is negligible compared to their horizontal MCC 
transportation rate (Kirch et al., 2012). The MCC rate is relatively fast, and it has been 
reported that insoluble particles are generally cleared from the conducting airways by 
MCC within 24 hours (Zhang et al., 2011). 
MCC of insoluble particles has been fully investigated in vivo with the rapid 
development of modern technologies, e.g. bronchoscope, radiography or external 
imaging of radiolabelled aerosol particles. These technologies are widely used to 
determine the rate of MCC in healthy subjects and patients with lung diseases. The rate of 
MCC is affected by different lung diseases. Betaman et al. have conducted a study to 
measure the tracheobronchial MCC on patients with mild and stable asthma (Bateman et 
al., 1983). A group of 25 patients with mild stable asthma and a control group of 25 
healthy subjects (matched for sex and age, non-smokers) inhaled 5 µm monodispersed 
polystyrene aerosol particles radiolabelled with technetium-99m (
99m
Tc). All treatments 
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were withdrawn 24 hours before the test. The effect of initial particle deposition and 
distribution was taken into account as well. Some amount of aerosol particles are 
deposited in the alveolar region, which are capable of escaping the MCC. Therefore, the 
alveolar deposition was subtracted from the whole lung retention curve to generate the 
true tracheobronchial MCC rate for asthmatic patients and healthy subjects. Despite the 
short transport path due to the obstructed airway in asthmatic patients, the 
tracheobronchial MCC rate was significantly slower for patients with asthma than healthy 
subjects. This impairment of mucociliary clearance for asthmatic patients has been 
previously reported (Daviskas et al., 2005; Del Donno et al., 2000; Foster et al., 1982; 
Pavia, 1984; Pavia et al., 1985). The impairment is attributed to a combination effect of 
inflammation mediators, change of function and structure of cilia, and mucus 
hypersecretion during stable or exacerbations of asthma (Del Donno et al., 2000).  
Mucociliary clearance is also reduced in patients with COPD, especially those with 
more predominant chronic bronchitis (Camner et al., 1973; Koblizek et al., 2011; Rogers, 
2005). Patients with COPD usually have chronic sputum production approximately up to 
100 mL per day (Snider et al., 1994) and the excess mucus produced by COPD patients is 
much more viscous than that of healthy subjects (Aikawa et al., 1989; Bhaskar et al., 
1986; Lopez-Vidriero and Reid, 1978; Rogers, 2000). These factors are often associated 
with recurrent chest infection (Prescott et al., 1995).  COPD patients also have an 
abnormal airway mucin composition. Mucins are long, thread-like high molecular weight 
glycoproteins which possess the viscosity of mucus. Mucins produced by COPD patients 
are less acidic than normal and have altered levels of glycosylation which may influence 
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mucus viscosity (Davies et al., 1996; Thornton et al., 1996).  Reduced mucociliary 
clearance for COPD patients can lead to accumulation of pathogens in the lung and result 
in further infections (Sethi, 2000). Bacterial damage to the airway tissue causes further 
loss of ciliated cells and increased  levels of mucus, which exacerbates the mucociliary 
dysfunction (Rogers, 2005).  
It has been suggested that in addition to their bronchodilator effect, long-acting β-
agonists (LABAs) are more capable of restoring the mucociliary dysfunction in asthma 
and COPD patients compared to short-acting β-agonists (SABAs).(Aalbers et al., 2002; 
Bennett, 2002; Devalia et al., 1992; Lindberg et al., 1995; Mahler et al., 1999; Melloni 
and Germouty, 1992; Pavia et al., 1987; Sackner, 1978; Yeates et al., 1986). Salmeterol 
and formoterol are two commonly used LABAs for treatment of asthma and COPD. 
Chambers et al. reported that salmeterol successfully enhanced the MCC by 60% 
compared with placebo in healthy volunteers (Chambers et al., 1999).  Salmeterol also 
demonstrated an increase in tracheobronchial clearance relative to placebo in patients 
with asthma. In another study conducted by Melloni et al., MCC was also significantly 
improved by inhaled formoterol compared to placebo in patients with chronic bronchitis 
(Melloni and Germouty, 1992). β-agonists are capable of increasing the intracellular 
cyclic adenosine monophosphate (cAMP) levels leading to acceleration of cilia beating 
frequency (Devalia et al., 1992; Tamaoki et al., 1989). Moreover, β-agonists can enhance 
the airway Cl
-
 secretion through the activation of the cystic fibrosis transmembrane 
regulator (CFTR), and results in mucus hydration (Salathe, 2002). The less viscous 
hydrated mucus is more easily transported by cilia. β-agonists also increase airway mucin 
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production and augment ion transport through epithelial; adddtionaly they can improve 
water efflux and promote mucus secretion (Phipps et al., 1982; Wanner, 1985). The 
overall effect is improving mucociliary clearance. Inhaled corticosteroids alone with their 
anti-inflammatory effect do not seem to have a direct effect on mucociliary clearance 
(Duchateau et al., 1986); however, combination therapy with inhaled a LABA and a 
corticosteroid was shown to treat the multicomponent nature of COPD and asthma 
(Rogers, 2005). 
Cystic fibrosis (CF) is a genetic disease that results in excess mucus production 
(Accurso, 2006). The genetic defect is in the cystic fibrosis transmembrane conductance 
regulator gene product. A cyclic AMP mediated membrane glycoprotein that forms a 
chloride channel but also intimately regulates the open probability of the sodium channel, 
ENaC, which is in charge of ion flux at epithelial surfaces (Wine, 1999). According to 
these functions, the pathophysiology of cystic fibrosis can be explained with two 
hypotheses: the excessive absorption of sodium ions resulting in impeded mucus 
movement (Boucher et al., 1986; Matsui et al., 1998), and defective chloride secretion 
leading to dehydration of secretions (Frizzell et al., 1986; Knowles et al., 1983). Studies 
have shown that patients with CF have reduced whole lung and regional clearance 
compared to healthy subjects (Armengot et al., 1997; Regnis et al., 1994; Robinson et al., 
2000). For instance, in one of the studies conducted by Regnis et al., MCC was 
significantly impaired in patients with CF and there was a strong correlation between 
mucociliary clearance and the severity of disease (higher level of impairment was 
observed for higher degree of severe disease) (Regnis et al., 1994).  
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Several other pulmonary diseases affect the mucociliary clearance in the respiratory 
tract. MCC is reduced by an acute respiratory infection, such as pneumonia (Jarstrand et 
al., 1974) and influenza (Camner et al., 1973). Chronic respiratory infections like 
bronchiectasis cause the impairment of mucociliary clearance (Daviskas et al., 1999; 
Daviskas et al., 2001). Chronic rhinosinusitis, which is an inflammation of the paranasal 
sinuses will cause patients to suffer from ineffective sinonasal mucociliary clearance 
(Antunes and Cohen, 2007). Pulmonary edema has also been reported to decrease 
mucociliary clearance to a lower level (Foster and Wagner, 2001). 
Cough is another important clearance mechanism in the upper airways when 
mucociliary clearance is impaired. Cough clearance was capable of eliminating up to 60% 
of the particles deposited in the central airways for patients with chronic bronchitis, 
compared to only 8% in healthy subjects (Puchelle et al., 1980).  
1.6.2 Alveolar macrophage uptake     
Macrophage uptake mainly occurs in the alveolar region. Insoluble or slowly 
dissolving particles that are able to penetrate to the alveolar region will be cleared by 
macrophage phagocytosis. Phagocytosis is described as occurring in four steps: 1) 
particles bind to the macrophage membrane by recognition of molecules on particle 
surface or via electrostatic forces; 2) transfer signal to activate receptors; 3) functionalize 
actin; and then 4) engulf particles into vesicular membrane and create phagosome based 
on the shape of the ingested particles (Geiser, 2010). Particle uptake by alveolar 
macrophages is dependent of geometric size. The optimum size for macrophage 
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phagocytosis is 1.5 to 3 µm (Oberdörster, 1988). Particles with size < 1 µm or >5 µm 
were found to have reduced macrophage uptake (Edwards et al., 1998; Edwards et al., 
1997; Tabata and Ikada, 1988). Macrophage phagocytosis is also affected by particle 
shape and surface chemistry (Champion and Mitragotri, 2006; Evora et al., 1998). Based 
on these properties, numerous of approaches have been developed to increase the lung 
retention of inhaled medicines. These approaches include manipulating the particle size 
(Bailey and Berkland, 2009; Edwards et al., 1997; El-Sherbiny et al., 2010; Tsapis et al., 
2002), shape (Crowder et al., 2002; Larhrib et al., 2003) and surface chemistry (Fu et al., 
2002; Gill et al., 2011; Lee et al., 2009) to reduce macrophage clearance.  
The uptake of particles by alveolar macrophages will be complete within 6 to 12 
hours after deposition (Zhang et al., 2011). Usually 50-75% of the particles are uptake by 
2-3 hours, more than 90% by 12 hours and almost 100% by 24 hours (Geiser, 2010). 
Once engulfed by the alveolar macrophages, particle carrying macrophages can be 
removed from the alveolar region by transportation upwards to the mucociliary escalator 
(Schmid et al., 2009); particles can also be disintegrated (e.g. by enzymes in lysosomes) 
or accumulated in the lymphatic system that drains both airways and alveoli, and 
accumulates in the lymph nodes (Geiser and Kreyling, 2010; Videira et al., 2002). Once 
particles are engulfed by macrophages, the clearance of these particle containing 
macrophages from the lung is relative slow, and usually takes days to months in humans 
(Oberdörster, 2007). 
Macrophage phagocytosis can be affected by pulmonary diseases. Lay et al. assessed 
the phagocytic activity of airway macrophages for patients with mild allergic asthma 
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compared to healthy subjects.  They monitored the radioactivity associated with cellular 
and supernatant in the sputum 2 hours after inhalation of radiolabelled aerosol (Lay et al., 
2009). Significant enhancement of macrophage phagocytosis for asthmatic patients was 
observed compared to healthy individuals. The increased particle uptake was not strictly 
a function of macrophage numbers and percentages, but has a strong correlation with the 
severity of asthma (Alexis et al., 2001; Lay et al., 2009).  The authors attributed this 
enhancement to a higher state of activation of airway phagocytes (including both 
macrophages and neutrophils) mediated by scavenger receptors such as MARCO15 or 
CD206 (macrophage mannose receptor). Moreover, changes of the airway surface liquid 
components (such as airway mucin, surfactant proteins, phospholipids, adenosine, and 
airway hydration) for asthmatic patients may also have an impact on macrophage 
phagocytic activity (Lay et al., 2009).  
It has been suggested that the alveolar macrophages (AMs) may act differently than 
airway macrophages in response to asthma. For patients with mild to moderate asthma 
with good symptom control, no differences of AMs phagocytic activity were observed 
compared to healthy subjects (Alexis et al., 2001; Huynh et al., 2005). However, AMs 
phagocytosis is functionally impaired for patients with severe asthma (Apiou-Sbirlea et 
al., 2010; Fitzpatrick et al., 2008; Huynh et al., 2005). The impairment of phagocytosis 
can be attributed to the increased activation of AMs from asthmatic patients. Asthmatic 
patients have higher production level of superoxide anion, pro-inflammatory cytokines, 
and regulators of inflammatory gene expression (e.g. histone acetyltransferase) than 
healthy subjects. Antigen stimulation and decreased production of anti-inflammatory 
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cytokines (e.g. IL-10) can further augment this impact. Therefore, the overall effects lead 
to the impairment of asthmatic AMs and increased apoptosis (Fitzpatrick et al., 2008). 
Similar findings have been reported for patients with COPD (Accurso, 2006; Berenson et 
al., 2006; Culpitt et al., 2003; Hodge et al., 2003; Russell et al., 2002; Taylor et al., 2010) 
and cystic fibrosis (Brennan et al., 2009; Vandivier et al., 2002) . AMs phagocytic 
activity is greatly reduced for patients with these diseases compared to healthy subjects. 
Although different diseases may have different mechanisms responsible for AMs 
impairment, it has been demonstrated that the underlying inflammation might play an 
important role here (Fitzpatrick et al., 2008).  
1.6.3 Clearance modeling 
A variety of computational models of pulmonary clearance have been reported 
(Gerrity et al., 1983; Sanchis et al., 1972).  Early models developed by Hofmann et 
al.(Hofmann et al., 1989) have simulated different clearance rate associated with different 
generations of the tracheobronchial airways (based on experimental data). Martonen et al. 
further upgraded the model of lung clearance as a function of spatial location within 
airway branching sites. Different clearance rates were simulated based on tubular airway 
segments, bifurcation zones, and carinal ridges (Martonen and Hofmann, 1991). Lung 
clearance will impact not only the retention time, but also the local distribution of inhaled 
particles. Therefore, it’s essential to incorporate the clearance models into the deposition 
models to accurately predict the fate of inhaled pharmaceuticals or inhalation toxicology.   
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1.7 Clinical Aspects 
We are optimistic about delivering medicines through the pulmonary route. Inhaled 
medicines tend to accumulate in the diseased areas of the lungs, while attaining reduced 
systemic exposure to protect sensitive organs from toxic drugs (Patton et al., 2010). 
However, dramatic changes may occur to the diseased lungs, which can impede the drugs 
from reaching and interacting with the target. For diseases in the upper airways, this 
might be insignificant, but the compromised pulmonary function/inflammation/ hyper-
secreted mucus may limit the ability to deliver high doses reproducibly and efficiently; 
for deep lung targeting approaches, drug delivery may be hindered by changes such as 
airway narrowing, mucus thickening, fibrosis and poor blood circulation (Forbes et al., 
2011). Therefore, risks still exist clinically for inhaled medicines in failing to deliver the 
therapeutics to their site of action. 
Inhalation therapies are very commonly used to relieve the symptoms of chronic 
lung diseases, such as COPD, CF and asthma. In the treatment of severe asthma (status 
asthmaticus), numerous studies have demonstrated that inhaled beta-agonists are not only 
more effective but also have significantly less side effects compared to intravenous beta-
agonists (Lalloo et al., 2013; Travers et al., 2012). Additionally, after lung transplantation, 
many transplant centers utilize inhaled antifungal therapy as prophylaxis against 
pulmonary fungal infections. Inhaled therapy has been shown to be effective without the 
numerous drug interactions seen with systemic antifungal therapy (Koo et al., 2012; 
Kuiper and Ruijgrok, 2009). In fact, inhaled medicines for treatment of lung infections or 
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interstitial lung diseases are rationale (Patton et al., 2010). In some cases, drugs reaching 
the diseased lesions of the lungs by systemic delivery are limited due to the blood-air 
barrier created by the diseases. While systemic delivery will be necessary to treat some 
forms of pulmonary diseases, inhaled medications either alone or in combination with 
systemic therapy have the potential to modify lung diseases by targeting therapy to the 
site of the underlying disease.   
One essential aspect when designing pharmaceutical aerosols to treat pulmonary 
disease is the dosimetry. Accurate dosimetry plays an important role in determining the 
efficacy and safety of inhaled medicines. To estimate the deposited dose, the FDA uses 
deposition fraction (DF) based on early publications for preclinical and clinical studies 
(Snipes et al., 1989; Wolff and Dorato, 1993). The DF that the FDA applies are as 
follows: 10% for rats, 25% for dogs and 100% for humans (Forbes et al., 2011). 
Although the default DFs are widely used for inhalation product development, it’s 
believed that the default DFs underestimate the deposition for animals and overestimate 
the deposition for humans (Forbes et al., 2011). Moreover, DFs are significantly affected 
by lung diseases factors. In silico modeling of aerosol deposition and clearance 
associated with lung diseases is potentially of great use in determining the dose regimen 
of inhaled medicines and designing inhalation therapy protocols. This type of modeling 
has the potential to reduce expensive pilot studies required in bringing new therapies to 
market.  
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1.8 Concluding Remarks 
The fate of inhaled medicines in the lungs plays an important role in determining the 
pharmacokinetics and pharmacodynamics of any inhaled drug. Several mechanisms are 
involved, including deposition, dissolution, absorption and clearance. These mechanisms 
occur nearly simultaneously, which makes it more difficult to study each of them 
individually. Lung diseases may alter the anatomic structure of the respiratory tract, the 
ventilatory conditions and the breathing pattern of patients. They can further affect the 
fate of inhaled pharmaceuticals. The biopharmaceutics of aerosol drugs in the lung is 
very complex with many processes involved. Table 7 summarized the impact of different 
lung diseases on each of these processes. When considering the impact of lung diseases 
on the fate of inhaled medicines, all these effects mentioned above may occur 
spontaneously in accordance with different lung diseases associated with different 
clinical manifestations. There is still a large underdeveloped area of research regarding 
how inhaled drugs will act in various diseased lung states. The advances on inhaled 
medicines and formulation designs will be hindered if we don’t address such questions. 
Nevertheless, it’s generally believed that treatment of most lung diseases with inhaled 
medicines still offers therapeutic and compliance benefits compared to delivery of drugs 
orally or intravenously. 
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Chapter 2 : In Vitro and In Vivo Performance of Dry Powder 
Inhalation Formulations: Comparison of Particles Prepared by Thin 
Film Freezing and Micronization 
 
2.1 Abstract 
Recently, inhaled immunosuppressive agents have attracted increasing attention for 
maintenance therapy following lung transplantation. The rationale for this delivery 
approach includes a more targeted and localized delivery to the diseased site with 
reduced systemic exposure, potentially leading to decreased adverse side effects. In this 
study, the in vitro and in vivo performance of an amorphous formulation prepared by thin 
film freezing (TFF) and a crystalline micronized formulation produced by milling was 
compared for Tacrolimus (TAC). Despite the relatively large geometric size, the TFF 
processed formulation was capable of achieving deep lung delivery due to its low density, 
highly porous and brittle characteristics. When emitted from a Miat® monodose inhaler, 
TFF processed TAC formulations exhibited a fine particle fraction (FPF) of 83.3% and a 
mass median aerodynamic diameter (MMAD) of 2.26 µm. Single dose 24-h 
pharmacokinetic studies in rats demonstrated that the TAC formulation prepared by TFF 
exhibited higher pulmonary bioavailability with a prolonged retention time in the lung, 
possibly due to decreased clearance (e.g., macrophage phagocytosis), compared to the 
micronized TAC formulation. Additionally, TFF formulation generated a lower systemic 
55 
 
TAC concentration with smaller variability than the micronized formulation following 
inhalation, potentially leading to reduced side effects related to the drug in systemic 
circulation. 
2.2 Introduction  
Since 1954, when the first long-term organ transplant was successfully performed, 
tremendous progress has been made in the field of surgical techniques and transplant 
medications. The importance of medicines that inhibit the immune system and prevent 
rejection of a transplanted organ is now better realized. Currently, lung transplantation is 
the least successful in terms of post-transplant survival rate among all the common solid 
organ transplants with survival rates of 88% at 3 months, 79% at 1 year, 64% at 3 years, 
53% at 5 years and 31% at 10 years [1]. The low survival rate is due to such conditions as 
bronchiolitis obliterans syndrome (BOS) associated with acute and chronic allograft 
rejection [1, 2]. Over the last two decades, immunosuppressive agents have gained more 
attention in treating rejection after organ and tissue transplantation. Present 
immunosuppressive therapy consists of a combination of a three orally administered  
drug regimen, a calcineurin inhibitor (Cyclosporine A or Tacrolimus), an antimetabolite 
(Mycophenolate mofetil or Azathioprine), and a corticosteroid [3]. 
Cyclosporine A (CsA) and Tacrolimus (TAC) are the two most commonly used 
calcineurin inhibitors for maintenance therapy after organ transplantation [4]. CsA was 
commercialized in 1983 by Novartis under the brand name Sandimmune® for systemic 
or oral treatment of acute and chronic transplant rejection. TAC, a more potent 
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immunosuppressive drug than CsA [5], can be administered twice daily for maintenance 
therapy (Prograf®, Astellas). Most recently, an extended release oral formulation of TAC 
was reported (Astagraf XL®, Astellas) and is taken once daily. It has been reported that 
TAC improves both short-term graft success and long-term patient survival rates with 
lower systemic toxicity compared to CsA [6-9]. In light of this, TAC is used more 
frequently than CsA [10]. However, the use of TAC is limited by its erratic oral 
bioavailability (varies from 4%-93%) and a variety of adverse side effects associated with 
elevated systemic concentrations over prolonged periods of therapy, such as 
nephrotoxicity, neurotoxicity, hypertension, diabetes mellitus, and increased risk of 
opportunistic infection [4]. 
Another approach to improve clinical outcomes of immunosuppressive agents in 
lung transplant patients is to administer the drugs via pulmonary inhalation. The rationale 
for this approach is more targeted and localized delivery with lower systemic exposure 
related to adverse side effects. Numerous studies reported inhaled CsA formulations to 
prevent rejection after lung transplantation [11-16]. One formulation, Cyclosporine 
Inhalation Solution (CIS) in propylene glycol (300 mg/4.8 mL, administered three times a 
week) has been investigated and demonstrated positive results [17]. Although CIS 
exhibited no statistical improvements in acute graft rejection compared to inhaled 
placebo, prevention of chronic rejection and patient survival rates were significantly 
improved [17].   This therapy was denied approval by the FDA due to uncertainties with 
the carrier vehicle and a lack of clinical efficacy [18]. Since TAC is more potent than 
CsA and formulated as a dry powder in the present study, it is possible that inhaled TAC 
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will achieve better clinical outcomes compared to inhaled CsA. Recently, alternative 
delivery systems containing TAC have been reported for inhalation applications to treat 
lung diseases, including a metered dose inhaler [19-21], nebulized solution in 70% 
ethanol [22, 23], nebulized nanoparticle dispersions [4, 24, 25], nano-liposomal dry 
powder inhalation [26] and respirable low-density brittle matrix particles [27]. Similar or 
slightly enhanced effects (suppression of airway inflammation or prevention of chronic 
and acute rejection after lung transplantation) and greatly reduced systemic exposure 
related to potentially decreased side effects were observed for inhaled TAC compared to 
oral or intramuscular injected TAC. Therefore, inhaled TAC is a feasible approach for 
maintenance therapy after lung transplantation. 
Pulmonary drug delivery by Dry Powder Inhalers (DPIs) has been well established 
as a valuable and efficient method for local and systemic treatment of diseases. Almost 
all the marketed DPIs are carried-based formulations, which have high dose variability 
and low delivery efficiency (%FPF ranging from 10%-35%) [27]. Recently, engineered 
particles capable of more efficient pulmonary delivery have gained increasing attention. 
Large, porous, low-density particles were first introduced by Edwards et al., which are 
able to achieve deep lung delivery despite their relatively large geometric size (up to 20 
µm) [28]. Since then a variety of technologies have been developed to enhance the 
pulmonary deposition efficiency of DPIs, including AIR® [29], PulmoSphere® [30, 31], 
Technosphere® [32], NanoCluster® [33] and brittle matrix particles prepared by Thin 
Film Freezing (TFF) [27]. Additionally, it has been reported that engineered particles 
with geometric diameter larger than 10 µm or smaller than 100 nm can escape from 
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macrophage phagocytosis, leading to prolonged lung retention time [34]. Moreover, the 
tailored physicochemical properties of engineered particles (e.g. amorphous, enhanced 
surface area, high porosity etc.) have demonstrated improved drug dissolution rate in the 
lung lining fluid [4, 35]. Therefore, TFF process was selected in this study to prepare the 
TAC formulation suitable for dry powder inhalation which was compared with traditional 
micronized particles.       
Lactose is the only excipient approved by the U.S. Food and Drug Administration 
(FDA), which can be used in DPIs at a high amount (up to 25 mg). Nearly all the carrier-
based DPI products on the market used lactose as carrier [27]. Mannitol (MAN) is also 
approved by the FDA as an excipient for inhalation, but limited to a very low content 
(0.051%). However, MAN can be inhaled up to doses of 365mg (Aridol®, Pharmaxis 
Ltd.) to assess bronchial hyperresponsivesness in patients. It has been reported by Watts 
et al. that respirable brittle matrix particles prepared by TFF were susceptible to moisture 
induced matrix collapse and hygroscopicity when lactose was used as excipient; in 
contrast, the aerosolization properties of TFF processed powders with MAN were not 
influenced by high humidity [27].  Therefore, MAN was chosen in this study due to its 
superior formulation stability.         
The objective of this study is to compare the in vitro and in vivo performance of dry 
powder inhalation formulations of TAC made by TFF to that made by micronization. We 
hypothesize that pulmonary delivery of the TFF processed formulation would yield 
higher deposition and more prolonged drug retention in the lung, compared to the 
micronized formulation, due to its aerodynamic properties and differences in clearance. 
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Additionally the TFF processed formulation will generate lower systemic concentration 
with smaller variability compared to micronized formulation, which could possibly lead 
to decreased side effects. To our knowledge, the pharmacokinetic properties of TAC 
following dry powder inhalation of amorphous TFF processed formulation versus 
crystalline micronized formulation have not been previously reported.  
2.3 Materials and methods 
2.3.1 Materials  
The following materials were purchased: Tacrolimus monohydrate (Haroui Pharma-
Chem Inc.,Irvine, CA); Ascomycin (ASCO, LC Laboratories, Woburn, MA);  Mannitol, 
HPLC grade acetonitrile and methanol (Fisher Scientific, Pittsburgh, PA); Polysorbate 80 
(Spectrum, Gardena, CA); Ethanol (Decon Labs, King of Prussia, PA); 0.9% sodium 
chloride for injection and heparin sodium 10,000 units/mL (TW Medical, Lago Vista, 
TX). 
2.3.2 Preparation of micronized TACMAN and TFF TACMAN 
Micronized TAC powders were prepared by wet ball milling followed by size 
reduction utilizing jet milling. Two grams of bulk TAC powders (mean particle size 84.7 
µm with 100% < 127.8 µm, as received from supplier) were dispersed in 25 mL of 
purified water in a ceramic jar with Zirconia grinding media (1/2 inch radius end cylinder) 
(US Stoneware, East Palestine, OH). The TAC dispersion was milled on a ball mill at 100 
rpm under room temperature for 24 hours , and the resulting slurry was combined with 
several successive washings of the ceramic jar and milling media using purified water. 
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The obtained TAC particle dispersion was pre-cooled in a -80°C freezer and lyophilized 
in a VirTis Advantage bench top tray lyophilizer (The VirTis Company, Inc., Gardiner, 
NY, USA). Further size reduction was achieved by feeding the obtained TAC dry powder 
into an air-jet mill (Aljet mill, Fluid Energy, Plumsteadville, PA, USA) with a feed 
pressure of 80 psi and a grinding pressure of 65 psi. Samples were collected and analyzed 
from the collecting chamber. Micronized MAN was produced by jet milling the bulk 
materials 4-5 times until the particle size reached the respirable range (1-5 µm). The 
particle size before and after milling was monitored using a Sympatec Helos laser 
diffraction instrument (Sympatec GmbH, Germany) equipped with a R3 lens. Briefly, the 
powder was dispersed in a non-solvent system (water for TAC, acetone for MAN) by 5 
seconds of sonication. The detector was activated at a minimum optical concentration of 
between 4% and 5%. Once the desirable size of the TAC and MAN particles were 
obtained, a physical mixture of micronized TAC and micronized MAN (1:1 by weight, 
micronized TACMAN) was acquired by blending the two powders using a tubular mixer. 
TFF TACMAN was prepared by Thin Film Freezing (TFF) technology. A detailed 
description of the TFF process was previously reported by Engstrom et al. [36]. Briefly, 
MAN was dissolved in purified water and TAC was dissolved in acetonitrile (ACN), 
respectively. A co-solvent mixture of ACN and water (60:40 v/v) containing TAC and 
MAN (1:1 w/w) was obtained by adequate mixing of the two solutions. The total solid 
concentration of the co-solvent was 0.75% (w/v). The co-solvent solution was rapidly 
frozen on a on a cryogenically cooled rotating stainless steel surface (−50 ± 3°C). The 
resulting thin film was removed from the surface by a scraper and maintained in the 
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frozen state in liquid nitrogen. Solvents were sublimated by lyophilization over 48 hours 
at pressures less than 200mTorr while the shelf temperature was gradually ramped from 
−40°C to 25°C. Prior to sample removal from the lyophilizer, dry nitrogen was purged 
into the chamber to equilibrate to atmospheric pressure and the final product was stored 
in a vacuum desiccator at room temperature.        
2.3.3 Differential Scanning Calorimetry (DSC) 
Thermal properties of micronized TACMAN, TFF TACMAN and each of their 
components were determined by a modulated temperature DSC (TA Instruments Model 
2920, New Castle, DE) equipped with a refrigerated cooling system. Dry nitrogen gas 
was purged through the DSC cell at a flow rate of 40 mL/min. Then 5–10 mg of samples 
were weighed into aluminum crimped pans (Kit 0219-0041, Perkin–Elmer Instruments, 
Norwalk, CT) and heated at a ramp rate of 10°C/min from 30 to 250 °C with a 
modulation temperature amplitude of 1°C/60 s. Data were analyzed using TA Universal 
Analysis 2000 software (TA Instruments, New Castle, DE). 
2.3.4 Powder X-ray Diffraction (XRD) 
The crystallinity of the same set of samples was evaluated by wide angle XRD (A 
Philips 1710 X-ray diffractometer, Cu Ka1 radiation, λ = 1.54059 Å, 40 kV, 40 mA). 
Samples were analyzed ranging from 5° to 40° at a 2θ step size of 0.05° and a dwell time 
of 2 seconds. 
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2.3.5 Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy 
(ATR-FTIR) 
Infrared spectra were obtained using a Bruker Equinox55 FTIR spectrophotometer 
(Karlsruhe, Germany) equipped with a deuterated triglycine sulfate detector and an 
attached attenuated total reflectance unit (Thermo Scientific, Hudson, NH). The same 
pressure was applied to all samples against the diamond crystal of the ATR cell by a 
pressure applicator with a torque knob monitor. Measurements were carried out with a 
scanning range of 800 to 4000 cm
-1
, resolution of 4 cm
-1
 and 16 scans per sample. Before 
each measurement background was scanned and subtracted, and all measurements were 
conducted at least three times to ensure the reproducibility.  
2.3.6 Scanning Electron Microscopy (SEM) 
SEM was employed to evaluate the morphology of both micronized and TFF 
particles. Prior to imaging, samples were mounted under vacuum onto aluminum stages 
with double-side carbon tape and coated using sputter coater (Electron Microscopy 
Sciences, USA) with platinum/palladium targeted for 12 nm thickness. Sample images 
were captured using a Leo 1530 scanning electron microscopy operating at an 
accelerating voltage of 10 kV.  
2.3.7 Brunauer–Emmett–Teller (BET) specific surface area analysis 
Specific surface area was determined by a Monosorb MS-21 surface area analyzer. 
The Monosorb utilizes a modified BET equation for extremely rapid, single-point 
determinations of surface area (P/P0 = 0.294). Samples were degassed at 30 °C by 
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nitrogen purging (20 psi) for at least 2 hours prior to measurement, and 30% Nitrogen in 
helium was used as the adsorbate gas. 
2.3.8 Geometric particle size measurement 
Geometric particle size of micronized TACMAN and TFF TACMAN aerosolized 
from a Miat monodose inhaler® (Miat, Milan, Italy) was measured by low angle light 
scattering technique using a Malvern Spraytec® (Malvern, UK) equipped with an 
inhalation cell and an induction port. The inhaler was loaded with a size 3 hypromellose 
(HPMC) capsule (Capsugel, Peapack, NJ) containing 3 mg of formulation and fitted to 
the mouth of the induction port by a silicone adapter. A pre-determined flow rate of 90 
L/min to achieve a 4 kPa pressure drop across the device was used for all measurements 
[37]. Data were collected over 4 seconds upon actuation when laser transmission dropped 
below 98%. Values reported are the average of at least three measurements.  
2.3.9 In vitro aerosol performance 
The aerodynamic properties of TFF TACMAN were investigated by a Next 
Generation Impactor (NGI) (MSP Corp., Shoreview, MN). A similar set up with the 
geometric particle size measurement was used. The Miat monodose inhaler® loaded with 
size 3 HPMC capsules containing 3 mg of formulation was secured to the induction port 
by a silicone adapter. Aerosols were generated over 2.7 seconds at a flow rate of 90 
L/min to achieve an inhalation volume of 4 L. Prior to actuation, surfaces of collection 
stages were coated with 1% polysorbate 80 in enthanol (v/v) and allowed to completely 
dry, as recommended by the European Pharmaceutical Aerosol Group (EPAG) [38]. The 
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cut-off size for each stage was calculated to be 6.48, 3.61, 2.30, 1.37, 0.76, 0.43 and 0.26 
µm from stages 1 to 7 and micro-orifice collector (MOC), respectively [39]. Following 
actuation, the deposited powders in the capsule, inhaler, adaptor, induction port, stages 1 
to 7 and MOC were collected by rinsing each area with 10 mL of methanol:water (90:10, 
v/v), which is the mobile phase for TAC quantification [40]. Briefly, TAC content was 
analyzed using a Dionex high performance liquid chromatography (HPLC) system 
equipped with a reversed phase C18 column (150 mm × 4.6 mm, 5 µm, 300 Å) with a 
Universal security guard column (Phenomenex, Torrance, CA). The mobile phase 
consisted of 90/10 (v/v) methanol/water and the injection volume was 20 µL. TAC was 
eluted over 6 minutes at a flow rate of 0.8 mL/min and a detection wavelength of 210 nm.  
The emitted dose (ED) was calculated as the percentage of drug emitted from the 
inhaler with respect to the total loaded dose into the capsule. The mass median 
aerodynamic diameter (MMAD), geometric standard deviation (GSD) and fine particle 
fraction (FPF) were calculated according to the USP 32-NF 27 General Chapter 601 [41]. 
A plot of cumulative percentage of mass less than stated aerodynamic diameter versus 
aerodynamic diameter (cut-off size for each stage) was built and fit to a 4 parameters 
logistic curve using Sigmaplot (Systat Software Inc., San Jose, CA). MMAD and GSD 
were calculated based on the drug deposition from stage 1 to 7 and MOC. FPF was 
determined as the percentage of aerosolized particles with a MMAD less than 5 µm with 
respect to the emitted dose.  
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2.3.10 In vivo pulmonary dosing in rats 
In vivo pharmacokinetic study was conducted using Sprague–Dawley rats (Charles 
River Laboratories, Inc., Wilmington, MA) in compliance with the Institutional Animal 
Care and Use Committee (IACUC) guidelines at The University of Texas at Austin. The 
rats (male and female: weighing from 250-300 g with an average weight of 270 g) were 
housed in a 12-h light/dark cycle with access to food and water ad libitum. Rats were 
subjected to one week of acclimation time to the housing environment and another week 
of restraint training in the nose-only dosing chamber. Powder aerosols were generated by 
a rotating brush generator (Palas RBG 1000, Palas GmbH, Karlsruhe, Germany). A 
detailed set up of the dosing apparatus was illustrated in Fig.2.1. Sixteen rats were dosed 
for each formulation group (12 non pre-catheterized rats for lung sample collection and 4 
pre-catheterized rats for blood sample collection). Prior to dosing, the exposure time for 
micronized TACMAN and TFF TACMAN were calculated to ensure that same TAC 
concentrations in the chamber were achieved. After exposure to the aerosolized powders, 
blood samples were withdrawn from a jugular vein catheter at 0.25, 1, 2, 4, 8 ,12 and 24 
hours and stored in a BD Vacutainer® blood collection tube at -80°C until analyzed. 
Equivalent volume of saline was replaced after each withdrawing. Three rats from each 
group were sacrificed at each time point (0.5, 1, 2, 8, and 24 hours) and lung samples 
were obtained. Prior to lung sample collection, a modified bronchoalveolar lavage (BAL) 
procedure was performed [26]. Briefly, the trachea was exposed by blunt dissection of 
the sternohyoideus muscle and a small incision was made to insert the lavage needle 
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outfitted with a 5 mL BD syringe. Approximately 3 mL of sterile phosphate buffered 
saline (PBS) was slowly injected to fill the lungs and the BAL fluid was withdrawn by 
gentle aspiration. This procedure was conducted twice so the total yield of BAL was 
between 4-5 mL. Then the lung was excised and stored in a -80°C freezer prior to 
analysis. 
2.3.11 Quantification of TAC concentration in the lung and blood  
 TAC concentration in the lung and blood was quantified by liquid chromatography 
mass spectrometry (LC/MS/MS). The LC/MS/MS system consisted of a Shimadzu SCL-
10A Controller, LC-10AD pump with a FCV-10AL mixing chamber, SIL-10AD 
autosampler, and an AB Sciex API 3200 tandem mass spectrometer with turbo ion spray. 
The analytical column (Grace Alltima C18, 4.6 x 150 mm, 5 µm, Alltech, Deerfield, IL) 
was maintained at 60
o
C during the chromatographic runs using a Shimadzu CTO-10A 
column oven. Mobile phase A contained 10 mM ammonium formate and 0.1% formic 
acid dissolved in HPLC grade methanol. Mobil phase B contained 10 mM ammonium 
formate and 0.1% formic acid dissolved in 90% HPLC grade methanol. The flow rate 
was maintained at 0.5 ml/min and TAC was eluted with a step gradient. The column was 
equilibrated with 100% mobile phase B. At 6.1 minutes after injection, the system was 
switched to 100% mobile phase A. Finally, at 15.1 min; the system was switched back to 
100% mobile phase B in preparation for the next injection. The TAC transition was 
detected at 931.6 Da (precursor ion) and the daughter ion was detected at 864.5 Da.  
Ascomycin (ASCO, internal standard) was detected at 809.574 Da and the daughter ion 
67 
 
was 756.34 Da. The ratio of the peak area of TAC to that of the internal standard 
(response ratio) for each unknown sample was compared against a linear regression of 
calibrator response ratios to quantify TAC. 
For extraction of TAC from whole blood sample, 100 µL of calibrator and unknown 
whole blood samples were mixed with 10 µL of 0.5 µg/mL ASCO (internal standard), 
300 µL of a solution containing 0.1% formic acid and 10 mM ammonium formate 
dissolved in 95% HPLC grade methanol. The samples were vortexed vigorously for 2 
min, and centrifuged at 15,000 g for 5 min. Supernatants were transferred to 1.5 ml 
microfilterfuge tubes and centrifuged at 15,000 g for 1 minute, then 40 µL of the final 
extracts were injected into the LC/MS/MS system. The concentration of TAC was 
expressed as ng/mL in the whole blood. 
TAC was extracted from rat lung tissue according to the following protocol. Briefly, 
100 mg of calibrator, control, and unknown tissue samples were mixed by sonication 
(three 5 seconds bursts) with 10 µL of 0.5 µg/mL ASCO (internal standard) and 300 µL 
of a solution containing 0.1% formic acid and 10 mM ammonium formate dissolved in 95% 
HPLC grade methanol. After sonication, the samples were vortexed vigorously for 2 min, 
and then centrifuged at 15,000 g for 5 min. Supernatants were transferred to 1.5 mL 
microfilterfuge tubes and centrifuged at 15,000 g for 1 minute and then 40 µL of the final 
extracts were injected into the LC/MS/MS. The concentration of TAC was expressed as 
ng/g in the lung tissue. 
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2.3.12 Pharmacokinetic and statistical analysis 
Plots of the concentration of TAC in the lung tissue and whole blood versus time 
were used to compare the pharmacokinetic behaviors of micronized TACMAN and TFF 
TACMAN.  The TAC concentration at the first time point (0.5 h) was considered as the 
initial dose. The TAC concentrations in the lung were normalized with respect to the 
TAC concentration at the first time point (0.5 h) and expressed as the percentage of initial 
concentration measured in the lung. A two-compartmental model was selected to 
calculate the pharmacokinetic parameters of TAC in the rat lung with the assistance of 
WinNonlin Professional Version 2.1 (Pharsight Corporation, Mountain View, CA). The 
area under the concentration versus time curve (AUC 0–24h) was calculated by the linear 
trapezoidal rule using average TAC concentrations in lung. Student’s t tests were 
conducted to determine the significance between the two dosing groups. For all tests, 
statistical significance was defined by p < 0.05. 
2.4 Results and discussion 
2.4.1 Crystallinity 
DSC was used to evaluate the thermal properties of micronized TACMAN, TFF 
TACMAN and their individual components (Fig.2.2). Micronized TAC displayed a 
melting peak at 127.16 °C and an enthalpy of fusion of 32.11 J/g; micronized MAN 
exhibited a melting peak at 171.17 °C and an enthalpy of fusion of 292.8 J/g, indicating 
that both components are crystalline after micronization. Both of the melting peaks of 
TAC and MAN were present in micronized TACMAN (1:1). For 1 gram of micronized 
69 
 
TACMAN (1:1), there were 0.497 gram of TAC and 0.503 gram of MAN, so the 
enthalpy of fusion for TAC endothermic peak based on the mass of TAC in micronized 
TACMAN (1:1) equals to 16.16/0.497 J/g, namely 32.52 J/g, which was very similar to 
the experimentally determined enthalpy of fusion of micronized TAC alone. Hence, 
nearly 100% of the TAC in micronized TACMAN (1:1) was crystalline [42]. Similarly 
the enthalpy of fusion for MAN endothermic peak based on the mass of MAN in 
micronized TACMAN (1:1) equals 149.8/0.503 = 297.8 J/g, which correlated to the 
enthalpy of fusion in micronized MAN alone, indicating 100% of the MAN in 
micronized TACMAN (1:1) was crystalline as well. TFF TAC only (no excipients, 100% 
potency) displayed a single glass transition temperature (Tg) of TAC at 75.42 °C. TFF 
MAN only exhibited an endothermic melting peak of MAN with an enthalpy of fusion 
(280.2 J/g) very close to the enthalpy of fusion of micronized MAN alone (292.8 J/g), 
meaning that the MAN in TFF MAN only was nearly 100% crystalline. In the TFF 
TACMAN (1:1) DSC profile, there was a single Tg (76.28 °C) corresponding to the Tg of 
TAC (75.42 °C) and no melting peak of TAC was detected, indicating the TAC in TFF 
TACMAN was amorphous; there was also an endothermic melting peak at 167.75 °C 
corresponding to the melting of MAN (169.09 °C) with an enthalpy of fusion of 138.2 J/g. 
Based on the potency (50.7%) of MAN in TFF TACMAN (1:1), the enthalpy of fusion 
for MAN endothermic peak based on the mass of MAN in TFF TACMAN (1:1) is equal 
to 138.2/50.7% = 272.6 J/g, similar to the melting of MAN alone, therefore, the MAN in 
TFF TACMAN (1:1) was 100% crystalline. In summary, TAC and MAN exhibited 
amorphous and crystalline properties, respectively, in TFF TACMAN (1:1). 
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In the XRD diffraction pattern (Fig.2.3), TAC exhibited intense characteristic 
crystalline peaks at 8.55, 12.75, 13.85, 14.25, 15.4, and 19.85 2-theta degrees in the 
micronized TAC, distinguished from the crystalline peaks of MAN at 14.7, 16.85, 18.85, 
20.5, 21.15, 24.65, and 36.1 2-theta degrees in micronized MAN. Micronized TACMAN 
(1:1) had both the characteristic peaks of TAC and MAN, indicating that both TAC and 
MAN were crystalline in micronized TACMAN (1:1). All of the characteristic peaks of 
TAC disappeared in TFF TAC only, indicating a highly amorphous morphology of TAC 
molecules [43]. In the TFF MAN only XRD profile, some of the characteristic peaks of 
MAN disappeared and the intensity of some peaks have been greatly reduced. It has been 
reported that the reduction of XRD peak intensity and broad halo peaks may be attributed 
to the reduction of particle size or change in crystalline microstructure [44]. As seen in 
the SEM images (Fig.2.5), TFF produced formulations exhibited a highly porous 
structure. Although it was not a complete particle size reduction due to aggregation if 
discrete particles are considered, the large pores between particles may cause molecules 
to lose their long-range crystalline order but still not be amorphous [44]. Therefore, the 
MAN in TFF MAN only exhibited crystalline properties. TFF TACMAN (1:1) displayed 
no characteristic crystalline peaks of TAC, but some broaden and intensity-reduced peaks 
of MAN corresponding to the peaks in TFF MAN only. Hence, the TAC in TFF 
TACMAN (1:1) was amorphous and MAN was crystalline.  
According to the DSC and XRD results, the crystalline state of TAC and MAN can 
be predicted during the entire manufacturing process. Initially, TAC was dissolved in 
acetonitrile (ACN) and MAN was dissolved in water. TAC molecules and MAN 
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molecules were homogenously dispersed in the co-solvent composed of ACN and water 
due to the high miscibility of ACN and water. During the TFF process, TAC and MAN 
are capable of transitioning into a glassy amorphous state because the extremely rapid 
cooling rate (estimated to be 10
6
 K/s) can prevent the nucleation and growth of crystals 
[43]. Then during the lyophilization process, TAC remained amorphous due to its high Tg 
(75.42 °C); MAN started to crystallize at its Tg (13 °C, measured from quench-cooled 
melt [45]). It has been reported that with a second component added into the MAN 
solution, the relative concentration threshold above which MAN will crystallize during 
the lyophilization process is about 30% (w/w), and this ratio is largely independent of the 
nature of the second solute [45]. In our case, TAC was considered as the second solute 
and the weight ratio of MAN in the formulation is about 50% (w/w), therefore, MAN was 
still crystalline after being freeze-dried. The seeding of crystalline MAN did not have an 
impact on TAC molecules because there is no interaction between TAC and MAN 
molecules according to the ATR-FTIR results (data shown in Fig.2.4; explanation 
follows below). Consequently the final product, TFF TACMAN (1:1), consists of both 
amorphous TAC domains and crystalline MAN domains.          
2.4.2 Molecular interactions investigated by ATR-FTIR 
ATR-FTIR was conducted in order to investigate the molecular interactions between 
TAC and MAN (Fig.2.4). The micronized TAC spectrum exhibits absorption bands of 
C=C stretch at 1638 cm
−1
, and resonating amidic C=O and ketonic C=O stretching 
vibrations at 1740, 1728 and 1693 cm
−1
, which can be distinguished from the spectrum of 
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micronized MAN with a broad OH stretch peak only [46]. In the micronized TACMAN 
(1:1) spectrum, all these bands were observed with the same absorbance, indicating that 
there were no interactions between TAC and MAN molecules that existed in this physical 
mixture of micronized TACMAN. However, in the spectrum of TFF TAC only, the band 
of C=C stretch shifted from 1638 cm
−1
 to 1650 cm
−1
, and the bands of
 
resonating amidic 
C=O and ketonic C=O stretching vibrations shifted from 1740, 1728 and 1693 to 1746, 
1716 and 1684 cm
−1, 
respectively. It has been reported that the absorbance of FTIR peaks 
are very sensitive to the crystal-packing configuration of different forms [47]. 
Accordingly the shiftiness of TAC absorption peaks in TFF TAC only was attributed to 
the state change from crystalline to amorphous. The same absorption peaks were 
observed in TFF TACMAN (1:1) compared with TFF TAC only, indicating there was no 
interaction between TAC and MAN molecules in TFF TACMAN. In summary, there is 
no evidence from the spectra of any hydrogen-bond interactions between tacrolimus and 
mannitol in either the micronized formulation or TFF formulation. 
2.4.3 Morphology, geometric particle size and aerodynamic properties 
Micronization was employed to physically reduce the particle size and maintain their 
original crystalline structure. Dry milling in a fluid energy mill (e.g., air-jet mill) is a 
typically used micronization technique. Despite the high energy input for jet milling, the 
process is extremely rapid and the materials are subjected to limited thermal stress [48]. 
However, the major issue with jet milling is the relatively low yield and loss of valuable 
materials during the repeated feeding and discharging compared to other milling 
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techniques [49]. Low energy wet ball milling is another widely used micronization 
technique. Theoretically, the yield from a wet ball milling process can reach up to 100%, 
but this micronization process requires a long time (hours to days) due to the low energy 
input [48]. Therefore, a combination of wet ball milling and jet milling was employed in 
the present study to achieve a high yield of micron-size drug particles and shorten the 
processing time. 
For pulmonary drug delivery, the optimum particle size is 1-5 µm [50]. In the present 
study, the mean particle size of TAC was reduced from 84.7 µm (bulk unprocessed TAC 
as received from supplier) to 8.6 µm (ranging from 1.5-22.8 µm) by wet ball milling for 
24 hours. No further size reduction was observed for longer milling times (up to one 
week) because the milling efficiency not only depends on the processing time, but it is 
also controlled by other parameters, such as the hardness of the material, nature of the 
milling medium and the wetting of the solids [35]. Following non-solvent removal by 
lyophilization, the size of the TAC particles was further reduced by feeding the dry TAC 
powders processed from wet ball milling to a jet mill. After one run on the jet mill, the 
mean particle size of TAC particles decreased from 8.6 µm (D10=1.5 µm, D90=22.8 µm) 
to 3.4 µm (D10=1.1 µm, D90=7.4 µm). Mannitol was micronized only by jet milling. 
After 3-4 runs on the jet mill, the particle size distribution of MAN was reduced to 
approximately the same size as the micronized TAC (D10=1.1 µm, D50=3.2 µm, 
D90=7.0 µm). The potency of TAC in micronized TACMAN (1:1) was 49.7%, indicating 
that adequate mixing was achieved and the mixture of micronized TAC and MAN is 
homogenous.  
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From the SEM images shown in Fig.2.5a, micronized TACMAN (1:1) is composed 
of fractured, irregular shaped particles with a wide size range and a large portion of 
particle agglomerates due to their cohesive behavior from electrostatic charge generated 
during the milling process [51]. On the other hand, TFF TACMAN (1:1) exhibited a 
highly porous structure composed of aggregated particle networking, in which discrete 
particles are barely distinguishable, as displayed in Fig.2.5b. The specific surface area of 
micronized TACMAN and TFF TACMAN was 2.87 and 32.45 m
2
/g (Table 2.1), 
respectively, corresponding to an effective particle diameter of 2.09 and 0.18 µm 
(assuming monodispersed unit density spherical particles).  
From a formulation perspective, the efficacy of drugs administered by pulmonary 
delivery is largely determined by the aerodynamic diameter of the aerosol particles [50]. 
In general, the optimum aerodynamic diameter for achieving deep lung deposition is 1-3 
µm [52]. The aerodynamic properties of TFF TACMAN were described in terms of the 
ED, MMAD, GSD, and FPF of the emitted dose, as illustrated in Fig.2.6. TFF TACMAN 
was capable of emitting 94.2% of the loaded dose from the device, because of the low 
density and highly porous structure of TFF particles, the turbulent airflow readily entered 
into the large pores to shear the aggregated particles apart and emit them from the device. 
The FPF and MMAD of TFF TACMAN were 83.3% and 2.26 µm, respectively, 
indicating that the shear and impaction forces generated by the air flow and the device 
were able to break the TFF brittle matrix particles into respirable low-density 
microparticles [27]. In addition, ED×FPF represents the percentage of total emitted dose 
that can achieve deep lung delivery; in this study, up to 78.5% of the TFF TACMAN can 
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be delivered to the lung using Miat® Monodose inhaler. GSD gives an indication of 
aerosol particle size distribution; TFF TACMAN had a relatively small aerodynamic size 
distribution with a GSD of 2.08 µm. From the results obtained, we can conclude that TFF 
TACMAN is suitable for deep lung delivery when incorporated into a commercially 
available DPI. 
Besides aerodynamic diameter, geometric particle size also plays an important role 
in determining the fate of aerosol particles in the lung. It is well known that the two main 
clearance mechanisms active in the lung are mucociliary clearance (MCC) in the central 
and small airways and macrophage phagocytosis in the alveolar region [53]. Particles 
with a geometric size larger than 6 µm are usually cleared by MCC in the ciliated region 
of the lung [54] and particles with diameters between 1-5 µm are preferably engulfed by 
alveolar macrophages in the alveoli [34]. The geometric size distribution of emitted 
aerosol particles was measured by dynamic light scattering following aerosol generation 
from the Miat® monodose inhaler. Micronized TACMAN exhibited a polydispersed size 
distribution with D10, D50 and D90 (diameter at which the cumulative sample volume 
was less than 10%, 50% and 90%) values of 0.93, 1.92 and 4.82 µm, respectively. On the 
other hand, aerosolized TFF TACMAN had a significantly larger geometric size (shown 
in Table 2.1, D10=4.39 µm, D50=17.84 µm, D90=64.49 µm). The aerodynamic diameter 
is calculated by the following equation: 
       √     ⁄  
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where Deq is the geometric diameter of the particle, ρ p is the particle density and Χ is 
the dynamic shape factor derived from a sphere. Hence, the aerodynamic diameter is not 
only dependent on geometric size, but also controllable by the particle density and shape. 
In the case of TFF TACMAN, assuming the shape of aerosolized particles is spherical, 
the calculated particle density is 0.016 g/cm
3
. Therefore, micronized TACMAN is likely 
to be cleared by macrophage phagocytosis when they reach the alveolar region due to 
their geometric size (1.92 µm); by contrast TFF TACMAN particles have the potential to 
escape from macrophage uptake while achieving deep lung delivery due to their 
relatively large geometric size (17.84 µm) and small aerodynamic diameter (2.26 µm).  
2.4.4 Pharmacokinetic analysis of micronized TACMAN verses TFF TACMAN 
The in vivo performance of inhaled micronized TACMAN and TFF TACMAN was 
investigated in a rat model. Rats were exposed via nose-only administration to 
aerosolized powders generated by a rotating brush generator (RBG). The delivered dose 
is calculated according to the equation below:   
           
where DD is the delivered dose (mg), C is the concentration of substance in air 
(mg/L), RMV is respiratory minute volume (i.e., the volume of air inhaled in one minute, 
L/min), and D is the exposure duration (min). The RMV for rats is calculated according 
to the formula: RMV (L/min) = 0.608 × BW (kg)
 0.852 
where BW represents the body 
weight of the tested subjects [55]. Of the delivered dose, only a small percentage will 
actually deposit in the lungs.  The deposition fraction of the delivered dose in rats 
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typically ranges between 10% and 5% of the delivered dose and has been shown to be 
dependent on particle size distribution [56]. 
Following exposure of the aerosolized powder, a 24-hour pharmacokinetic profile 
was determined in lung tissue and blood for micronized TACMAN and TFF TACMAN. 
For comparison purposes, TAC concentrations in the lung were normalized with respect 
to the concentration at the first time point (0.5 h) and expressed as a percentage of initial 
doses (%) and determined as a function of time (Fig.2.7). The TAC concentrations in the 
lung at 0.5 hour were 265.8 ng/g for TFF TACMAN and 122.6 ng/g for micronized 
TACMAN. A 2-compartment model (Fig.2.9) was used to calculate the PK parameters in 
the lung for micronized TACMAN and TFF TACMAN and the results are shown in 
Table 2.2. In the model, the rate constant K10 describes the lung clearance rate, which 
represents a combination effect of mucociliary clearance, macrophage phagocytosis and 
metabolism. K12 and K21 are exchange rates of drug between the lung and the blood 
compartments. As seen in Table 2.2, K10 of micronized TACMAN (2.64 h
-1
) is 
approximately 4.7 times greater than that of TFF TACMAN (0.56 h
-1
), indicating that the 
lung clearance rate is much faster for micronized particles compared to aerosolized TFF 
particles. Micronized TACMAN exhibited faster clearance rate because most of the 
particles tend to be engulfed by macrophages due to the phagocytic favorable geometric 
size (mean 1.92 µm); in contrast, TFF TACMAN had a relatively large geometric particle 
size (mean 17.84 µm). Based on estimations from macrophage uptake studies, it could be 
predicted that more than 90% of the TFF particles are capable of escaping clearance from 
macrophage phagocytosis [57]. It is also possible that TFF particles undergo rapid 
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dissolution, leaving little to be cleared by macrophages compared to the more kinetically 
stable crystalline particles [4, 24].  The lung clearance trends observed from the two 
formulations differ significantly from 2 h to 8 h. This difference is supported by prior 
macrophage clearance studies where 50-75% of the micron-sized particles are cleared by 
macrophages by 2-3 h and 90% or more by 10 h [58]. The systemic absorption rate of 
TAC from the lung epithelium (K12) is slightly higher for TFF TACMAN (2.16 h
-1
) 
compared to micronized TACMAN (1.70 h
-1). According to Fick’s first law, K12 is 
proportional to the membrane permeability, surface area over which the drug is deposited 
and the drug concentration in the lung lining fluids. While in humans deposition of 
particles less than 3 µm is thought to occur predominately in the deep lung. Kuehl et al. 
showed that in mice and rats particles with different mean sizes (0.5, 1, 3, 5 µm) 
deposited along the entire airway including oral/nasal, trachea/bronchi, and lungs [56]. In 
the present study, the aerodynamic size distribution of the aerosol generated by the RBG 
was very similar for TFF TACMAN and micronized TACMAN (with MMAD values 
measured at about 1.5 µm). Hence the regional deposition pattern should be comparable 
for the two formulations. Accordingly, the drug permeability due to regional deposition 
should be similar for both formulations. Drug permeability, however, may not be the 
same in both formulations due to the differences in physicochemical properties described 
earlier. It has been reported that amorphous TAC can reach up to 10-times supersaturated 
solubility compared to crystalline TAC [4].  These in vitro studies provided evidence that 
TFF TACMAN dissolved more rapidly and to a greater extent than the micronized blend 
in this study. Additionally, the faster dissolution rate of amorphous TFF TACMAN may 
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make it less susceptible to mucociliary clearance since drug is rapidly dissolved and able 
to permeate into airway tissues. All of the effects mentioned above could contribute to 
enhanced pulmonary bioavailability of TFF TACMAN. If we normalize the data by 
assuming that the same dose was delivered in both groups, the average AUC 0-24h in the 
lung is 1707.47 ng*hr/g and 729.53 ng*hr/g for TFF TACMAN and micronized 
TACMAN, respectively. Once the TAC dissolves in the lung lining fluid, it is available 
for absorption and will either remain in pulmonary tissue or cross into the blood stream. 
As evident from several investigations of inhaled TAC in rodents, absorbed TAC 
molecules seem to preferably remain in lung tissue rather than going into systemic 
circulation [4, 19-23, 25]. The higher lung AUC of TFF TACMAN can be attributed to 
the faster dissolution rate, leading to more TAC molecules available for absorption into 
the lung tissue. The overall clearance rate (CL) is much slower for TFF TACMAN 
compared with micronized TACMAN (data presented in Table 2.1). The nearly 2.3-times 
greater AUC and slower clearance rate in the lung tissue for TFF TACMAN 
demonstrated that this formulation is favorable for localized lung delivery while a 
micronized formulation may be more susceptible to the lung’s clearance mechanisms.  
The systemic TAC concentration after exposure to the aerosolized powder of 
micronized TACMAN and TFF TACMAN is illustrated in Fig.2.8. Based on a larger 
K12 value, the systemic absorption rate of TAC through the lung epithelium is slightly 
faster for amorphous TFF particles compared to crystalline blend.  However, a much 
higher and more variable blood concentration of TAC was observed for micronized 
TACMAN compared to TFF TACMAN, likely due to clearance and subsequently 
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gastrointestinal (GI) tract absorption. Once deposited, the slowly dissolving micronized 
crystalline particles undergo mucociliary clearance towards the mouth where they are 
eventually mixed with saliva and swallowed, then available for absorption via the GI tract 
into systemic circulation. The more variable blood concentration of TAC that was found 
for micronized TACMAN at 2h and 4h was due to its erratic oral bioavailability (varies 
from 4%-93%) [59]. Additionally, it is possible that the undissolved micronized particles 
are engulfed by macrophages, which can then be slowly transported along the alveolar 
surface to the mucociliary escalator or translocation to the intersitium and lymph nodes 
[53, 54]. As shown in Fig.2.8, besides the first peak concentrations around 1h, there was 
a significant second peak at either 4 or 8 hours for both experimental groups, which 
corresponded to the re-absorption of TAC from the GI tract. The calculation of K20 
(TAC clearance rate from the blood) is based on the elimination phase in the plasma 
compartment. However, if TAC was still being absorbed at 8 hours, it’s not feasible to 
determine K20 just based on the testing period (up to 24 hours) in this study. A slightly 
increasing trend of TAC concentration in the blood towards the end of the test (from 12h 
to 24h) was observed for the micronized group, possibly because the TAC-carrying 
macrophages slowly moved to the mucociliary escalator and were absorbed orally or 
TAC transported to the lymphatic system and eventually partitioned into circulation [60]. 
On the other hand, the blood concentration of TAC for TFF TACMAN group remained 
low (1-5 ng/mL) for the entire testing period (24h) due to reduced clearance and oral 
absorption. In summary, by delivering TAC as a more rapidly dissolving formulation, 
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TFF TACMAN is able to provide bioavailable TAC on the pulmonary epithelium and 
avoid the lung’s clearance mechanisms, while minimizing systemic concentration. 
2.5 Conclusion 
Engineered particles containing tacrolimus and mannitol were successfully prepared 
by TFF.  The amorphous TFF-processed formulation demonstrated excellent 
aerodynamic properties when incorporated into a commercially available DPI. Following 
a single dose dry powder inhalation study in a rat model, TFF-processed powders 
achieved a significantly higher pulmonary bioavailability with longer lung retention time 
compared to micronized powders, likely due to their ability to avoid pulmonary clearance 
mechanisms (mucociliary clearance and macrophage uptake). Additionally lower 
systemic exposure with small intersubject variability was observed for the TFF-processed 
formulation, which could potentially reduce adverse side effects. In this study, production 
of inhaled tacrolimus by TFF has demonstrated the capability to localize therapeutic drug 
levels to the lungs more effectively than an inhaled micronized blend and minimize 
systemic level.  
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Chapter 3 : Effect of Processing Parameters on the Physicochemical and 
Aerodynamic Properties of Respirable Brittle Matrix Powders 
Produced by Thin Film Freezing 
 
3.1 Abstract 
Thin film freezing (TFF) was employed to produce brittle matrix powders, capable 
of forming into respirable low-density particles upon aerosolization. The objective of this 
study is to investigate the impact of processing parameters in the TFF process on the 
physicochemical and aerodynamic properties of the resulting formulations. TFF 
formulation produced at the higher freezing rate (cryogenic surface temperature: -140°C) 
showed greater specific surface area, higher porosity and lower density, compared to the 
TFF formulation prepared at the intermediate freezing rate (cryogenic surface 
temperature: -50 °C) and slow freezing rate (slow freezing on the shelf of -40°C). All of 
these enhanced properties induced by faster freezing rate further contributed to an 
increased fine particle fraction (FPF) of the obtained formulations. Moreover, an 
increasing trend of FPF was observed for these TFF powders when the initial solid 
concentration was reduced, probably due to the enhanced brittleness. The variation of the 
freezing rate and initial solid loading in the TFF process enabled the production of 
formulations with tailored physicochemical properties and brittleness, leading to 
improved aerodynamic performance. 
89 
 
3.2 Introduction 
Recently, engineered particles capable of more efficient pulmonary delivery have 
gained increasing attention [1, 2]. Particle engineering technologies such as milling, spray 
drying, spray-freeze drying, supercritical fluid processing, and controlled precipitation 
have been widely used to produce dry powders suitable for inhalation [3-7]. Large porous 
low-density particles were first introduced by Edwards et al., which are able to achieve 
deep lung delivery despite their relatively large geometric size (up to 20 µm) while 
prolonged the pulmonary retention time due to their ability of escaping the lung’s natural 
clearance mechanisms [8]. Since then a variety of technologies have been proposed to 
enhance the pulmonary deposition efficiency of DPIs, including AIR® [9], 
PulmoSphere® [10, 11], Technosphere® [12], and NanoCluster® [13]. In addition to the 
enhanced delivery efficiency, there are several other advantages for engineered particles 
in pulmonary drug delivery. For instance, it has been reported that particles with 
geometric diameter larger than 10 µm or smaller than 100 nm can escape from 
macrophage phagocytosis, leading to prolonged lung retention time, which enables 
substantial time for dissolution and absorption [14, 15]. Moreover, the tailored 
physicochemical properties of engineered particles (e.g. amorphous, enhanced surface 
area, high porosity etc.) have demonstrated improved drug dissolution rate in the lung 
lining fluid and potentially improved aerodynamic properties [16, 17]. A innovative 
particle engineering process, thin film freezing (TFF) has been shown to produce brittle 
matrix powders, which can be sheared into respirable low-density microparticles upon 
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aerosolization from a passive dry powder inhaler [18].Therefore, TFF process was 
selected in this study to investigate formulations suitable for dry powder inhalation.       
In the TFF process, frozen thin films are formed rapidly by applying a solution 
containing the API(s) and excipients directly onto a cryogenic substrate surface. Then the 
frozen thin films are removed from the surface and maintained in the frozen state until 
solvent is removed by lyophilization [19]. This rapid freezing process is capable of 
preventing the crystallization and aggregation of the dissolved solute, resulting in low-
density brittle matrix structure [18]. Mannitol (MAN) is a commonly used excipient in 
developing lyophilized pharmaceutical products [20]. One of the reasons for the 
widespread use of MAN as a bulking agent in the lyophilizaiton process is due to its 
tendency to crystallize from frozen aqueous solutions, leading to a physically stable 
freeze-dried product [20]. Moreover, the high melting temperature of the mannitol/ice 
eutectic mixture (around -1.5 °C) makes it possible to achieve primary drying at a 
relatively high temperature, therefore improves process efficiency [21]. Another potential 
application of MAN is acting as a lyoprotectant for biopharmaceuticals in the freeze-
dried process [22, 23]. Watts et al. found that respirable brittle matrix particles prepared 
by TFF were susceptible to moisture induced matrix collapse and very hygroscopic, 
leading to altered aerodynamic performance when amorphous content (e.g. lactose and 
raffinose) was present; in contrast, the aerosolization properties of crystalline TFF 
processed powders with MAN were not influenced by high humidity [18].  Therefore, 
MAN was chosen in this study due to its superior formulation stability and robustness to 
moisture. Due to its lack of absorption in the ultraviolet-visible (UV-Vis) spectral region, 
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it’s difficult to quantify MAN using high-pressure liquid chromatography (HPLC) with a 
UV/Vis detector. Hence a commonly used dye compound Rhodamine B (RHO, peak 
absorption at 525nm) was added in the composition (1% w/w), to facilitate the 
quantification of these TFF formulations.        
It has been previously demonstrated by our research group that different solvent 
systems used in the TFF process (e.g. tert-butanol versus acetonitrile) generated thin 
films with different thickness and diameter, which impacted the freezing rate, and 
consequently affected the morphology of the resulting TFF formulations [19]. Engstrom 
et al. used the same solvent system (i.e. water) but differed the temperature of the 
cryogenic substrate in the TFF process. Thin films with different geometry and cooling 
rate was observed, resulting in different surface morphology of the TFF powders [24]. 
Theoretical modeling of the cooling time was correlated to the infrared imaging results 
[19, 24]. However, the physicochemical and aerodynamic properties of these TFF 
powders prepared at different freezing rates have not been fully investigated. Therefore, 
in the preset study, formulations were prepared at three different freezing rates (TFF with 
cryogenic substrate temperature at -140°C, -50°C and freezing directly on the shelf of the 
lyophilizer for slow freezing) and their impact on the physicochemical and aerodynamic 
properties was evaluated. Moreover, the influence of different initial solid concentrations 
on the aerosolization properties of the TFF powders was investigated.  
The objectives of this study are to prepare MAN formulations that are suitable for 
dry powder inhalation using thin film freezing technology (TFF) and evaluate how 
process parameters (e.g. freezing rate and initial solid loading) impact the morphology 
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and aerodynamic properties of the obtaining formulations. We hypothesize that: (1) 
formulations prepared at different freezing rate will exhibit different physicochemical 
properties, leading to variable aerodynamic performances; (2) the initial solid 
concentrations will affect the density and brittleness of the TFF processed powders, 
further impact the aerosolization properties of the resulting formulations.   
3.3 Materials and Methods 
3.3.1 Materials  
The following materials were purchased: Rhodamine B, Mannitol, HPLC grade 
acetonitrile and methanol (Fisher Scientific, Pittsburgh, PA); Polysorbate 80 (Spectrum, 
Gardena, CA); Ethanol (Decon Labs, King of Prussia, PA). 
3.3.2 Formulation Preparation 
Thin Film Freezing (TFF) technique was employed in this study to prepare the 
formulations. A detailed description of the TFF process was demonstrated by Engstrom 
et al. [24]. Briefly, RHO and MAN was dissolved in purified water at different solid 
concentrations (0.5%, 1%, 5% and 10%, w/v). Same initial solid loading (1%, w/v) was 
used to compare different freezing rates. A solution of RHO and MAN (1:99, w/w) was 
rapidly frozen on a on a cryogenically cooled rotating stainless steel surface (−50°C or -
140°C). The resulting thin films were removed from the surface by a scraper and 
maintained in the frozen state in liquid nitrogen. For the slow freezing RHOMAN, 
solution of RHO and MAN was slowly frozen in scintillation vials on the shelf (SFS, -
40°C). Following the freezing processes, solvents were sublimated by lyophilization over 
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48 hours at pressures less than 200mTorr while the shelf temperature was gradually 
ramped from −40°C to 25°C. Prior to sample removal from the lyophilizer, dry nitrogen 
was purged into the chamber to equilibrate to atmospheric pressure and the final product 
was stored in a vacuum desiccator at room temperature. 
3.3.3 Differential Scanning Calorimetry (DSC) 
Thermal properties of the bulk powders and each of their components were 
determined by a modulated temperature DSC (TA Instruments Model 2920, New Castle, 
DE) equipped with a refrigerated cooling system. Dry nitrogen gas was purged through 
the DSC cell at a flow rate of 40 mL/min. 5–10 mg of samples were weighed into 
aluminum crimped pans (Kit 0219-0041, Perkin–Elmer Instruments, Norwalk, CT) and 
heated at a ramp rate of 10°C/min from 30 to 250 °C with a modulation temperature 
amplitude of 1°C/60 s. Data were analyzed using TA Universal Analysis 2000 software 
(TA Instruments, New Castle, DE). 
3.3.4 Powder X-ray Diffraction (XRD) 
The crystallinity of the same set of samples was evaluated by wide angle XRD (A 
Philips 1710 X-ray diffractometer, Cu Ka1 radiation, λ = 1.54059 Å, 40 kV, 40 mA). 
Samples were analyzed ranging from 5° to 40° at a 2θ step size of 0.05° and a dwell time 
of 2 s. 
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3.3.5 Powder Bulk Density and Porosity 
Bulk density of powders was determined according to a modified method from USP 
<616>. Briefly, bulk powders were gently poured into a 5 mL graduated cylinder. The 
mass and volume were recorded to calculate the bulk density of the powders.  
The porosity of the bulk powders was measured by mercury porosimetry 
(Micromeritics, Norcross, GA). The sample was evacuated 5 minutes and the mercury 
filling pressure was set to be 1.73 Pa. The standard equilibration time used in the 
experiments was 10 seconds. The results were calculated by multiple linear regression 
analysis. 
3.3.6 Brunauer–Emmett–Teller (BET) specific surface area analysis 
Specific surface area was determined by a Monosorb MS-21 surface area analyzer. 
The Monosorb utilizes a modified BET equation for extremely rapid, single-point 
determinations of surface area (P/P0 = 0.294). Samples were degassed at 30 °C by 
nitrogen purging (20 psi) for at least 2 hours prior to measurement. 30% Nitrogen in 
helium was used as the adsorbate gas. 
3.3.7 Aerodynamic Performance 
The aerodynamic properties of different formulations were investigated by a Next 
Generation Impactor (NGI) (MSP Corp., Shoreview, MN). Miat monodose inhaler® 
loaded with size 3 HPMC capsules containing approximately 3 mg of formulation was 
secured to the induction port by a silicone adapter. A pre-determined flow rate of 90 
L/min to achieve a 4 kPa pressure drop across the device was used for all measurements. 
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Aerosols were generated over 2.7 s at a flow rate of 90 L/min to achieve an inhalation 
volume of 4 L. Prior to actuation, surfaces of the collection stages were coated with 1% 
polysorbate 80 in enthanol (v/v) and allowed to completly dry, which is recommended by 
the European Pharmaceutical Aerosol Group (EPAG) [25]. The cut-off size for each 
stage was calculated to be 6.48, 3.61, 2.30, 1.37, 0.76, 0.43 and 0.26 µm from stages 1 to 
7 and micro-orifice collector (MOC), respectively [26]. Following actuation, the 
deposited powders in the capsule, inhaler, adaptor, induction port, stages 1 to 7 and MOC 
was collected by rinsing with 10 mL of acetonitrile (ACN):water (70:30, v/v), which is 
the mobile phase for RHO quantification [27]. Briefly, RHO content was analyzed using 
a Dionex high performance liquid chromatography (HPLC) system equipped with a 
reversed phase C18 column (150 mm × 4.6 mm, 5 µm, 300 Å) with a Universal security 
guard column (Phenomenex, Torrance, CA). The mobile phase consisted of 70/30 (v/v) 
ACN/water and the injection volume was 20 µL. RHO eluted at approximately 5 minutes 
with a flow rate of 1.0 mL/min and a detection wavelength of 525 nm.  
Total Emitted dose (TED) was calculated as the percentage of drug emitted from the 
inhaler with respect to the total loaded dose into the capsule. Mass median aerodynamic 
diameter (MMAD), geometric standard deviation (GSD) and fine particle fraction (FPF) 
were calculated according to the USP 32-NF 27 General Chapter 601 [28]. Plot of 
cumulative percentage of mass less than stated aerodynamic diameter versus 
aerodynamic diameter (cut-off size for each stage) was built and fit to a 4 parameters 
logistic curve using Sigmaplot (Systat Software Inc, San Jose, CA). MMAD and GSD 
were calculated based on the drug deposition from stage 1 to 7 and MOC. FPF was 
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determined as the percentage of aerosolized particles with a MMAD less than 5 µm with 
respect to the delivered dose.  
3.3.8 Geometric Particle Size Measurement 
Geometric size of aerosolized particles from a Miat monodose inhaler® (Miat, Milan, 
Italy) was measured by low angle light scattering technique using a Malvern Spraytec® 
(Malvern, UK) equipped with an inhalation cell and an induction port. Inhaler was loaded 
with a size 3 hypromellose (HPMC) capsule (Capsugel, Peapack, NJ) containing 3 mg of 
formulation and fitted to the mouth of the induction port by a silicone adapter. Aerosols 
were generated over 2.7 s at a flow rate of 90 L/min to achieve an inhalation volume of 4 
L. Data was collected over 3 s upon actuation when laser transmission dropped below 
98%. Values reported are the average of at least three measurements.  
3.3.9 Mechanical Testing 
The mechanical properties of the bulk powders were evaluated using a Texture 
Analyzer (TA.XT.plus, Stable Micro Systems, Godalming, United Kingdom) equipped 
with a 5 kg load cell. A cylindrical stainless steel probe with a diameter of 7 mm was 
used in the study and test was conducted at a speed of 1 mm/s and a maximal immersion 
into the bulk powders of 10 mm. Compression mode was applied in the test. The 
cylindrical probe compresses the bulk powders by proceeding at constant speed and the 
force needed for the immersion was recorded. The resulting immersion force represents 
the force requires for breakage of the bulk powders. At the end of the immersion, the 
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probe returned to its original height. Measurements were performed in triplicate and 
averaged. 
3.4 Results and Discussion 
3.4.1 Formulations prepared by different freezing processes 
The phenomena of droplet spreading and freezing upon impinging with a cryogenic 
solid substrate in the TFF process have been previously studied [19, 24]. The diameter of 
the frozen cylindrical disks were measured across two directions and averaged for 10 
droplets. The measured average diameters for both TFF formulations prepared at 
different freezing temperatures (-50°C and -140°C) were 12 mm. The thickness of the 
frozen cylindrical disks was then calculated to be 176.8 µm by assuming that a droplet 
impacting on the cryogenic substrate will deform into a cylindrical disk with the same 
volume as the original droplet. It was previously demonstrated with infrared imaging of 
cooling thin films that the water droplets’ spreading occurred within the first 10 
milliseconds upon impact with the cryogenic surface, which is much shorter than the 
freezing time (hundred to thousand milliseconds) [24]. The cooling rate of the thin films 
can be predicted with a simplified analytical heat transfer model, which was validated 
with experimental IR data [19].  
A one-dimensional heat transfer for a finite slab with an insulating boundary 
condition on the top and a constant temperature boundary condition on the bottom above 
is described by the following equation: 
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where x is the distance from the top of the spread droplet, T(x,t) is the temperature in 
the film reaching distance x and at time t, Tcryo is the temperature of the cryogenic 
substrate in contact with the bottom thin film surface, and L is the film thickness [29]. 
Then the cooling time (ms) was calculated by determining the time t, it takes for the top 
surface of the thin film at x=0 with thickness L to reach a given temperature T (freezing 
point of water, 273.15K). The cooling rate (K/s) was determined by dividing the 
temperature change at the top surface of the thin film (from room temperature to freezing 
point of water) by the cooling time. As shown in Table 3.1, the calculated cooling time 
for TFF process at -140°C and -50°C were 106ms (cooling rate 2.36×10
2
 K/s) and 148ms 
(cooling rate 1.69×10
2
 K/s), respectively. For the sample frozen directly on the tray of the 
lyophilizer, the observed cooling time was more than 10
6
ms with a very slow cooling rate 
(<2.5×10
-5
 K/s). 
Table 3.1 presents the physicochemical properties of powders prepared at different 
freezing rates. The degree of supercooling, the freezing rate, and the time required for 
complete solidification directly affected the ice crystal formation and growth during the 
freezing process, eventually impact the morphology and porosity of the final dried 
product after sublimation of ice [30, 31]. As illustrated in Fig.3.1, at high cooling rate 
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(left figure), the very thin water channels between the frozen ice crystals reduce the 
chance of aggregation and growth of MAN crystals. for an intermediate cooling rate 
(middle figure), MAN particle growth is intermediately prevented by the slightly thicker 
water domains left between the ice crystals; for extremely low freezing rate (right figure), 
fewer ice crystal domains were created compared to the rapid cooling process, leaving 
very thick channel of water domain, thus higher chance for crystalline growth of MAN 
particles [24]. Therefore, less aggregated MAN crystal particles resulted from TFF (-
140°C) exhibited higher porosity (6.8%) than TFF formulation prepared at -50°C (4.2%). 
Due to the enhancement of porosity by increasing the cooling rate, TFF RHOMAN (-
140°C) exhibited SSA of 77.4 m
2
/g, approximately 2-times greater than TFF RHOMAN 
(-50°C) with SSA of 38.6 m
2
/g. Moreover, increases of porosity lead to enlargement of 
the gap between matrix particles, further resulted in a lower bulk density for TFF 
RHOMAN (-140°C; 10.38 mg/cm
3
) compared to TFF RHOMAN (-50°C; 12.31 mg/cm
3
). 
For the slow freezing on the shelf formulation, due to the increased chance for MAN 
particles to aggregate, porosity was undetectable, the surface area is extremely low (0.8 
m
2
/g ) and the bulk density (26.84 mg/cm
3
) was higher than TFF formulations.  
The crystallinity of these powders was analyzed by DSC and XRD. In the DSC 
profiles shown in Fig.3.2, bulk RHO melts and discomposes simultaneously around 
210°C; bulk MAN has a melting point around 170°C with an enthalpy of fusion about 
280 J/g; physical mixture of RHOMAN (1:99, w/w) displayed a single melting point 
around 170 °C with enthalpy of fusion similar to bulk MAN. All the three formulations 
prepared by different freezing processes exhibited a single melting point of MAN with 
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enthalpy of fusion similar to bulk MAN, indicating that MAN is completely crystalline in 
the formulations. Since the potency of RHO is only 1% (w/w), DSC was unable to detect 
its thermal properties in the physical mixture and three other formulations [32]. XRD 
demonstrated that RHO after processed by TFF was completely amorphous (Fig.3.3). 
Crystallinity still existed in MAN after processed by TFF with characteristic peaks at 
9.05, 14.7, 16.85, 18.85, 20.5, 21.15, 24.65, and 36.1 2-theta degrees. These peaks were 
also found in all the other three formulations prepared by different freezing process and 
the peak intensity (which is a reflection of crystallinity) increased with the increases of 
freezing rate, TFF -140°C >TFF -50°C >slow freezing on the shelf of -40°C (SFS). 
    The aerodynamic properties of the powders are shown in Fig.3.4. The TED of the 
three formulations was comparable (around 85%), indicating that for all formulations 
aerosolized particles upon shearing and impaction were small enough to exit the capsule 
and enter into the impactor. The FPFs of TFF RHOMAN (-140°C), TFF RHOMAN (-
50°C) and SFS RHOMAN (-40°C) were calculated to be 72.2%, 59.6% and 23.3%, 
respectively. Correlated to the FPF, TFF RHOMAN (-140°C) exhibited the smallest 
MMAD (2.47 µm) and GSD (2.59 µm); TFF RHOMAN (-50°C) had an intermediate 
MMAD of 3.29 µm and GSD of 3.11 µm; SFS RHOMAN (-40°C) displayed the largest 
MMAD (6.34 µm) and GSD (4.89 µm). All the results above demonstrated that faster 
freezing rate generated powders with better aerodynamic performance (higher FPF, lower 
MMAD and GSD). As illustrated in Fig.3.1, higher freezing rate results in an increased 
porosity, further lead to a thinner matrix structure of the obtained formulation. Therefore, 
when the same shear and impaction forces was generated from the air flow and DPI 
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device, more brittle fracture occurs when a thinner matrix structure is present in the 
formulation.   These theories correlated with the results (Fig.3.4) that TFF RHOMAN (-
140°C) exhibited better aerodynamic performance (highest FPF, smallest MMAD and 
GSD) than TFF RHOMAN (-50°C). On the other hand, the lower porosity and surface 
area of SFS RHOMAN (-40°C) resulted in very low FPF, large MMAD and GSD.  
The geometric size distribution of formulations prepared at different freezing rates is 
demonstrated in Fig.3.5. For TFF processed formulations, a wider size distribution was 
observed for TFF RHOMAN (-50°C) with D10, D50 and D90 (diameter at which the 
cumulative sample density was under 10%, 50% and 90%) values of 9.32, 39.84 and 
184.26 µm compared to TFF RHOMAN (-140°C, D10: 5.74 µm, D50: 33.46 µm and 
93.9 µm). SFS RHOMAN (-40°C) exhibited a double peak with D10, D50 and D90 
values of 10.74, 49.85 and 339.64 µm, respectively. The mean geometric size of 
aerosolized particles decreased as the freezing rate increased (Table 3.2), confirming that 
formulations with higher porosity and thinner matrix structure were brittle fractured into 
geometrically smaller particles. As we know, the aerodynamic diameter is calculated by 
the following equation: 
       √     ⁄  
Where Deq is the geometric diameter of the particle, ρ p is the particle density and Χ 
is the dynamic shape factor derivate from sphere. Dynamic shape factor of 1.50, MMAD 
and D50 were used for calculation of particle density based on the equation above [18]. 
The calculated density shown in Table 3.2 was well correlated to the measured bulk 
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density for all three formulations, indicating that only brittle fracture occurred with no 
powder collapse or compressions during the aerosolization process.  
In order to understand the underlying mechanism of why powders freezing at 
different rates have different aerodynamic performance, the mechanical force necessary 
for breakage of the matrix powders was determined using a Texture Analyzer by 
immersion a cylindrical probe into the bulk powders. No significant difference in terms 
of immersion force was observed for the three formulations prepared by different 
freezing processes (data not shown), indicating that there is no significant difference in 
term of mechanical properties between formulations prepared by different freezing 
processes. In summary, TFF formulations prepared at higher freezing rate lead to 
powders with superior aerodynamic properties, compared to TFF processed powders at 
intermediate cooling rate and slow freezing on the shelf products.        
3.4.2 TFF powders prepared at different initial solid concentrations 
To determine the influence of solids concentration during TFF production, several 
different solution concentrations were investigated, 0.5%, 1%, 5% and 10%. The same 
freezing process (TFF at -50°C) was employed for comparison purposes. As illustrated in 
Fig.3.6, similar thin water channels will be generated between the ice crystal domains. 
However, due to the different initial solid concentrations, the molecules’ intensity is 
different at the same thin water channels. For TFF formulations prepared at higher initial 
solid loading (right figure), there are many more molecules mobilized in the water 
channels between the ice crystal domains, increase the chance for MAN crystals to grow 
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and aggregate until completely frozen; For TFF formulations prepared at lower initial 
concentration (left figure), fewer MAN molecules were mobilized between the ice crystal 
domain, leading to less aggregated MAN particles with higher porosity.  
The aerodynamic performance of TFF RHOMAN prepared at different solid 
concentrations determined by NGI is shown in Fig.3.7. No difference was observed 
between 0.5% TFF RHOMAN and 1% TFF RHOMAN in terms of TED (around 85%), 
indicating that the shear and impaction forces generated by air flow and device were able 
to break the bulk matrix particles into aerosol particles that were small enough to exit the 
holes on the pierced capsule. When initial solid loading increased to 5% and 10%, the 
TED of the TFF formulations decreased to 52.9% and 30.9%, respectively, because there 
were certain amount of matrix particles can’t be fractured into particles that were smaller 
enough to exit the capsule. A significantly decreasing trend of FPF for these TFF 
formulations was observed (Fig.3.7) when the initial solid concentrations increased, 
because higher solid concentration resulted in TFF powders with less porosity, thinner 
matrix structure and lower density, which is beneficial for the aerosolization properties. 
Correspondingly, MMAD and GSD increased when the initial solid concentration 
increased.  
The geometric particle size distribution of aerosol particles for TFF RHOMAN 
prepared at different solid concentrations is shwon in Fig.3.8. The mean geometric 
particle size (D50) of aerosolized TFF particles decreased as the initial solid loading 
increased, probably because more brittle fracture occurred when thinner matrix structure 
was generated from lower initial solid concentration in the TFF process. The resulting 
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bulk density of the powders prepared at different concentrations is displayed in Table 3.3. 
The bulk density of TFF RHOMAN (0.5%) and TFF RHOMAN (1%) were slightly 
higher than the theoretical values. Since minor brittle fracture was induced during the 
collection process due to the high brittleness of the TFF formulations prepared at lower 
solid concentration, fractured matrix particles tend to collapse with each other and 
causing the measured bulk density to be higher than the theoretical value. However, for 
TFF formulations prepared at relatively high solid concentrations (5% and 10%, w/v), it’s 
difficult to fracture the matrix particles due to their low brittleness, hence the measured 
bulk densities correlated well with the theoretical values. A linear relationship was found 
for the bulk density to the initial solid concentrations (Fig.3.9). Therefore, in the TFF 
process, initial solid concentration is an essential parameter that can be manipulated to 
control the bulk density of the resulting formulations, further optimize the aerodynamic 
performance of TFF processed brittle matrix powders.  
Mechanical testing revealed marked differences of the immersion forces for bulk 
TFF powders prepared with different solid concentrations, as shown in Fig.3.10. In this 
experiment, a probe was moved at a set rate through a powder bed of each concentration 
of TFF formulation.  The data was analyzed to report the resulting forces versus 
compaction of a given mass of powder.  By comparing the resulting forces over a given 
mass for each powder formulation, we can determine which matrix resulted in more 
brittle fracture/deformation and which resisted fraction/deformation.  Not surprisingly, 10% 
TFF powders resisted compaction more than formulations made at lower concentrations 
likely due to a stronger, less brittle, matrix structure.  . The slopes for 0.5%, 1%, 5% and 
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10% TFF RHOMAN were 0.109, 0.254, 1.635 and 3.019 N/g, respectively (Fig.3.10).  
The value of these slopes increased with the increases of initial solid loading, indicating 
that TFF formulations prepared at higher solid concentration generated less fracturable 
powders, which may require higher energy to achieve brittle fracture during the 
aerosolization process. Since the TFF particles need to be fractured into respirable 
particles during the aerosolization process, we can conclude that brittleness and fragility 
of TFF matrix powders demonstrated by a smaller slope in the immersion-force curve is 
essential for a good aerodynamic performance. By lowering the initial solid 
concentrations in the TFF process, it is possible to improve the fracture abilities of TFF 
processed powders and accordingly the aerodynamic properties.             
3.5 Conclusion  
Engineered particles containing bulking agent mannitol and Rhodamine B as a 
marker were successfully prepared by TFF process. Despite their relatively large size 
(50-100 µm), these brittle matrix powders were highly respirable due to their low density 
and brittle nature. By varying the freezing process, different cooling time and freezing 
rate were achieved. Formulations prepared at higher freezing rate exhibited greater 
surface area, higher porosity and lower density, which further lead to better aerodynamic 
performance (higher FPF) for these brittle matrix powders. A linear relationship of the 
resulting bulk density to the initial solid concentrations was observed for TFF processed 
powders. Moreover, as decreasing the initial solid concentration, the FPF of TFF 
formulations demonstrated an increasing trend due to the lower density and enhanced 
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brittleness. Therefore, the aerodynamic properties of TFF produced formulations can be 
optimized by altering the freezing rate and initial solid concentrations of the TFF process.    
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Tables 
Table 1.1 Current inhaled pharmaceuticals for treatment of lung diseases (a) and systemic applications on 
the market or undergoing clinical studies. 
(a) 
 
Therapeutic usage Drug 
classifications 
Drugs Inhalation device Current 
development status COPD and asthma Short-a ting beta-
2 agonist 
(SABAs) 
Salbutamol (albuterol) Nebulizer, pMDI, 
DPI 
Marketed 
Fenoterol pMDI Marketed outside 
of US Pirbuterol Nebulizer, pMDI Discontinued by 
Dec.2013 Terbutaline DPI Marketed 
Levalbuterol pMDI Marketed 
Long-acting beta-
2 agonist 
(LABAs) 
Salmeterol  pMDI, DPI Marketed 
Formeterol  pMDI, DPI Marketed 
Arformoterol Nebulizer Marketed 
Indacaterol DPI Marketed 
Anticholinergic 
agents 
Ipratropium bromide Nebulizer, pMDI Marketed 
Tiotropium bromide pMDI, DPI Marketed 
Aclidinium bromide DPI Marketed 
Oxitropium bromide pMDI Outside of US 
Glycopyrronium 
bromide 
DPI Outside of US 
Inhaled 
corticosteroids 
(ICS) 
Beclomethasone 
dipropionate 
Nebulizer, pMDI, 
DPI 
Marketed 
Budesonide Nebulizer, DPI Marketed 
Fluticasone propionate pMDI, DPI Marketed 
Mometasone furoate pMDI, DPI Marketed 
Ciclesonide pMDI Marketed 
Combination 
therapy 
 
Fenoterol/Ipratropium pMDI Marketed 
salbuterol/Ipratropium pMDI Marketed 
Formeterol/Budesonide pMDI, DPI Marketed 
Formeterol/Mometason
e 
DPI Marketed 
Salmeterol/Fluticasone pMDI, DPI Marketed 
 Glycopyrronium/formot
erol 
pMDI Phase II 
Sugar alcohol Mannitol DPI Marketed 
Antisense AIR-645 Nebulizer Phase II 
oligonucleotides PXSTPI-1100 Nebulizer Preclinical 
ATL-1102 Nebulizer Preclinical 
CpG 
oligonucleotides 
QAX-935 (IMO-2134) Nebulizer Phaes I 
siRNA Excellair Nebulizer Phase II 
Cystic fibrosis Antibiotics Tobramycin Nebulizer, DPI Marketed 
 
Aztreonam Nebulizer Marketed 
 
Colistimethate sodium Nebulizer Pilot trials 
 
Liposomal 
ciprofloxacin 
Nebulizer Phase II 
 Liposomal amikacin Nebulizer Phase III 
 
Levofloxacin Nebulizer Phase III 
 PUR118 DPI Phase I 
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Table 1.1a continued 
 
Mucous 
mobilizers 
Dornase alfa Nebulizer Outside of US 
 
Lancovutide  Nebulizer Phase II 
Restore Airway 
Surface Liquid 
Hypertonic saline Nebulizer Marketed  
Mannitol  DPI Phase III 
Antiproteases Alpha1-antitrypsin Nebulizer Phase II 
MRSA lung 
infections 
Vancomycin DPI Phase II 
Respiratory Distress 
Syndrome 
Pulmonary 
surfactant 
Phospholipids/surfactan
t proteins 
Endo-tracheal tube Marketed 
Respiratory Syncytial 
Virus 
Antiviral MDT-637 Novel inhaler Phase II 
There are more than 70 pipeline medicines in development for asthma and more than 50 pipeline medicines 
in development for COPD. For more information, please refer to Medicines in Development Asthma 2012 
report and Medicines in Development COPD 2012 report presented by Pharmaceutical Research and 
Manufacturers of America (available on PhRMA’s web site). 
 
(b) 
 
Therapeutic usage Drug classifications Drugs Inhalation 
device 
Current development 
status Analgesia Opioids Fentanyl  Novel inhaler Phase II 
  
Liposomal fentanyl  Nebulizer Phase II 
Migrane Triptan Sumatriptan  Intranasal 
powder 
Phase III 
Diabetes Peptides Insulin DPI Phase III 
  
Glucagon-like 
peptide  
DPI Phase I 
Nerve gas 
poisoning 
Nerve agent antidote Atropine Novel inhaler Phase I 
Parkinson's 
Disease 
Psychoactive drug Levodopa DPI Phase II 
Schizophrenia Antipsychotic medicati
on 
Loxapine DPI Outside of US 
DPI, dry powder inhaler; pMDI, pressurized Metered Dose Inhaler. Adapted with permission from Ungaro 
et al. J Pharm Pharmacol 64, 1217-1235 (2012). Other sources are from Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) web site, Global Initiative for Asthma (GINA) web site and 
http://clinicaltrials.gov/ 
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Table 1.2 Most commonly occurring lung diseases, their definitions, causes, symptoms and pathophysiology. 
Common lung 
diseases 
Definitions Causes Symptoms Pathophysiology 
Chronic obstructive 
pulmonary disease 
(COPD) 
COPD is an ill-defined term that is often 
applied to patients who have emphysema, 
chronic bronchitis, or a mixture of the two.  
 
Smoking 
air pollution 
Shortness of breath, 
cough, cough up 
mucus 
Chronic bronchitis: hypertrophy of mucous glands 
in large bronchi, inflammation in small airways, 
excessive mucus production. Emphysema: loss of 
alveolar walls, destruction of capillary bed, small 
airways narrowed and reduced in number. 
Asthma Asthma is characterized by increased 
responsiveness of the airways to various 
stimuli and is manifested by widespread 
narrowing of the airways that change in 
severity, either spontaneously or as a result 
of treatment. 
Allergy 
Smoking 
exercise 
Coughing, Wheezing 
Shortness of breath 
Chest tightness, pain, 
or pressure 
Hypertrophied smooth muscle and mucus glands, 
bronchoconstriction, edema of the bronchial wall, 
thick tenacious and slow-moving mucus 
Cystic Fibrosis Cystic fibrosis is an autosomal recessive 
genetic disorder that affects most critically 
the lungs, and also the pancreas, liver, and 
intestine. It is characterized by abnormal 
transport of chloride and sodium across an 
epithelium, leading to thick, viscous 
secretions. 
Genetic Salty-tasting skin, 
coughing, wheezing, 
Difficulty breathing, 
Big appetite but poor 
weight gain 
thick and sticky mucus, excessive absorption of 
sodium ions, defective chloride secretion  
Pneumonia Inflammation of the lung parenchyma 
associated with alveolar filling by exudate. 
Bacteria, Virus, 
Fungi, Parasites 
Fever, cough, malaise, 
pleuritic pain 
Alveoli crammed with cells, necrosis of tissue, 
lung abscess 
Pulmonary edema Abnormal accumulation of fluid in the 
extravascular spaces and tissues of the lung. 
Heart failure, 
lung injury 
shortness of breath, 
Chest discomfort or 
heaviness, Fatigue etc. 
Engorgement of interstitial tissue, increased 
lymph flow and widen lymphatic, fluid-filled 
alveoli 
Lung carcinoma Lung carcinoma is a disease characterized by 
uncontrolled cell growth in tissues of the 
lung.  
Smoking Coughing, weight loss, 
shortness of breath. 
Small cell lung cancers (SCLC) form central 
tumors and non-small cell lung cancers (NSCLC) 
form both central and peripheral tumors. 
Pulmonary Embolus Obstruction of blood flow to one or more 
arteries of the lung by a thrombus (other 
emboli – fat, air, and amniotic fluid) lodged 
in pulmonary vessels. 
Blood clot in a 
vein on the leg 
or on the pelvis 
Shortness of breath, 
low blood oxygen 
levels. 
Venous thrombi formed, static of blood, alteration 
in the blood coagulation system, abnormal vessel 
wall 
Pulmonary arterial 
hypertension (PAH) 
PAH is a progressive disorder characterized 
by abnormally high blood pressure 
(hypertension) in the pulmonary artery, the 
blood vessel that carries blood from the heart 
to the lungs.  
Cause unclear 
genetic  
Shortness of breath, 
chest pain 
Hypertrophy and thickening of artery wall, 
increased capillary permeability, reduced lymph 
drainage 
All the definitions in this table are cited from West 2012. Pulmonary pathophysiology : the essentials, 8th ed. Wolters Kluwer/Lippincott Williams & 
Wilkins Health, Philadelphia. 
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Table 1.3 Advanced technologies for production of dry powder formulations designated for inhalation. 
 
Technologies Company Preparation Process Device 
Respirable 
Fraction (%) 
References 
AIR® Alkermes Spray drying Spinhaler® up to 49% Vanbever et al., 1999 
PulmoSphere® Novartis 
Spray drying of 
double emulsion 
Eclipse® DPI up to 60% Duddu et al., 2002 
Technosphere® MannKind 
Acid-induced particle 
self-assembly 
MedTone® 
DPI 
up to 57% 
Richardson and Boss, 
2007 
NanoCluster® Savara Salt flocculation N/A up to 84% Plumley et al., 2009 
Thin Film 
Freezing 
Patented by Univ. 
of Texas at Austin 
Rapid freezing Handihaler® up to 74% Watts et al., 2013 
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Table 1.4 Particle deposition equations at different flow conditions for the three deposition mechanisms. 
 
Flow 
conditions 
Deposition mechanisms 
Inertial impaction P(I) Sedimentation P(S) Diffusion P(D) 
Laminar 
 
 
  (    )  ⁄
       ( )  
 
 
  (    )  ⁄        ( )   (
 
 
)  ⁄    
Turbulent       (
   
 
) 
 
     (
     ( )    ( ( ))
  ( )
) 
 
     (
         ⁄   ( )  ⁄  ( )
 ( ) ( ) 
 
   ( )  ( )  ( ),    ( )    ( ( ))  ( ),      ( )  ( ) ( )  
ϕ(I): Inclination of generation I airway with respect to horizontal (°); θ(I): Angle of bend of generation (°); τ: 
particle relaxation time; G: Gravitational constant=980 cm/s2; L(I): Length of airway generation I; D(I): Diameter of 
generation I; U(I): mean air velocity in generation I; Re(I): Airflow Reynolds number in generation I; d: particle 
diffusion coefficient; t(I): residence time of particle in generation I; V: particle Stroke terminal settling speed. 
Reprinted with permission from Martonen etal. Adv Eng Softw 28, 359-364 (1997). 
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Table 1.5 List of input and output parameters for aerosol deposition models. 
 
Input parameters Output parameters 
Subject characteristics: 
height, weight, age 
Functional Residual Capacity(FRC) 
Forced expiratoryvolumein1s(FEV1) 
Images: 
Planar gamma camera lungs 
Planar gamma camera oropharynx 
SPECT/CT of lungs 
SPECT/CT of lungs with partial volume correction 
SPECT/CT of oropharynx 
Ventilatory parameters: 
Tidal volume 
Inhalation time 
Breath hold time 
Exhalation time 
Posture 
Percentage of inhaled deposition by airway section: 
Extrathoracic 
Trachea/bronchi 
Right lung 
Left lung 
Exhaled 
Aerosol characteristics: 
Mass median aerodynamic diameter 
Geometric standard deviation 
Particle size distribution curve 
Humidity 
Carrier gas 
Spatial measures of deposition: 
One dimensional curves of variation of deposition with shell number 
2D c/p ratio (absolute and volume normalized) 
3D c/p ratio (absolute and volume normalized) 
Airway morphology: 
Images of segmented airway 
Airway measures of deposition: 
One dimensional curves of variation of deposition with generation 
number 
24 h clearance 
Conducting airways deposition fraction 
Adapted with permission from Conway et al. J Aerosol Sci 52: 1–17 (2013). 
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Table 1.6 Breathing pattern of adults at two different conditions, sedentary and light activity. 
 
  
Tidal volume 
(ml) 
Frequency 
(breaths/min) 
Minute 
volume (L) 
Inspiratory 
flow rate 
(L/min) 
Sedentary 500 14 7 14 
Light Activity 1291 15.5 20 40 
Adapted with permission from Martonen et al. Pharm Res 12, 96-102 (1995) 
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Table 1.7 The impact of lung diseases on the fate of inhaled medicines for each of these processes. 
 
Processes 
involved in the 
fate of inhaled 
medicines 
The impact of lung diseases on these different processes 
Deposition 
For obstructive lung diseases, deposition on the diseased sites ↑ and deposition in the alveoli ↓ 
For pulmonary fibrosis, deposition ↓ in the whole lung, and heterogeneity ↑  
Absorption 
For obstructive lung diseases including lung cancer, systemic absorption ↓ 
For pulmonary vascular diseases, systemic absorption ↓ 
For pulmonary fibrosis, both pulmonary and systemic absorption ↓ 
For chronic airway inflammations and pulmonary edema, systemic absorption ↑ 
Caveolae mediated transcytosis impacted by different lung diseases 
Clearance 
For COPD, asthma and CF, mucociliary clearance (MCC) rate ↓ 
For pneumonia and influenza, MCC rate↓ 
For bronchiectasis, chronic rhinosinusitis and pulmonary edema, MCC rate↓ 
For chronic bronchitis, cough clearance ↑ 
Airway macrophage phagocytosis ↑ for asthma 
Mild to moderate asthma, alveolar macrophage (AMs) phagocytosis unchanged; for severe 
asthma, AMs impaired 
For COPD, AMs phagocytosis ↓  
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Table 2.1 Specific surface area (SSA), geometric particle size distribution of micronized TACMAN (1:1) 
and TFF TACMAN (1:1). Values are expressed as mean±SD (n=3). 
 
 
  
Formulation 
TAC 
potency 
(%) 
 
SSA 
(m2/g) 
Calculated particle 
diameter (µm) 
Geometric Particle Size (µm) 
 D10 D50 D90   
Micronized 
TACMAN (1:1) 
49.7  2.87±0.16 2.09 0.93±0.03 1.92±0.05 4.82±0.08   
TFF TACMAN 
(1:1) 
50.3  32.45±3.28 0.18 4.39±0.21 17.84±0.57 64.49±2.89   
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Table 2.2 Lung pharmacokinetic parameters of TFF TACMAN (1:1) and micronized TACMAN (1:1) 
following single dose exposure to dry powder aerosols generated from a rotating brush generator. All the 
parameters were calculated based on average lung concentration (n=5).  
 
Pharmacokinetic 
parameters 
TFF 
TACMAN 
(1:1) 
Micronized 
TACMAN (1:1) 
AUC 0-24h(ng*hr/g) 1707.47 729.53 
K10 (h-1) 0.56 2.64 
K12 (h-1) 2.16 1.70 
K21 (h-1) 0.20 0.45 
Cmax (ng/g) 948.20 1924.83 
CL (ng/(hr*ng/g) 2.93 6.85 
MRT (hr) 21.18 1.82 
Model fit (R2) 0.9985 0.9999 
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Table 3.1 Physicochemical properties of TFF RHOMAN (-140°C), TFF RHOMAN (-50°C) and shelf 
lyophilized RHOMAN. 
 
 
  
Freezing process 
Cooling 
time (ms) 
Cooling 
rate (K/s) 
SSA 
(m2/g) 
Bulk 
Density  
(10-3g/cm3) 
Porosity (%) 
TFF at -140°C, then lyophilized 106 2.36×102 77.4±2.5 10.42±0.68 6.8 
TFF at -50°C, then lyophilized 148 1.69×102 38.6±1.7 12.31±1.12 4.2 
Shelf lyophilized, precool to -50°C >106 <2.5×10-5 0.8±0.0 26.84±2.53 Undetectable 
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Table 3.2 Bulk density and calculated aerosolized particle density based on measured geometric and 
aerodynamic diameters of TFF RHOMAN prepared by different freezing processes. 
 
Formulations 
Bulk Density 
 (10-3g/cm3) 
MMAD 
(µm) 
D50 
(µm) 
Dynamic 
shape factor 
(X) 
Calculated 
density  
(10-3g/cm3) 
TFF at -140°C 10.42±0.68 2.47 33.46 1.50 8.17 
TFF at -50°C 12.31±1.12 3.29 39.84 1.50 10.23 
Shelf lyophilized 26.84±2.53 6.34 49.85 1.50 24.26 
 
  
121 
 
Table 3.3 Bulk density and calculated aerosolized particle density based on measured geometric and 
aerodynamic diameters of TFF RHOMAN prepared at different solid concentrations (0.5%, 1%, 5% and 
10%). 
 
Solid Concentration 
(w/v) of TFF 
RHOMAN 
Theoretical Bulk Density 
(mg/cm3) 
Measured Bulk 
Density (mg/cm3) 
0.5 5 6.84±0.68 
1 10 12.31±1.12 
5 50 48.75±4.64 
10 100 100.64±9.61 
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Table A.1 Summary of prior arts of inhaled Tacrolimus. 
Formulations, Delivery 
Systems 
Animal Model Results references 
Inhaled TAC aerosol puffs 
(50 µg/puff), oral TAC (1 
mg/kg) 
Inhibits 
Antigen-
Induced 
Airway 
Inflammation 
in Guinea Pigs 
Suppress airway inflammation in guinea 
pigs; effect of 3 inhaled puffs was almost 
equal to that of 1 mg/kg administered by 
the oral route. Following inhalation of 3 
puffs, TAC concentration in blood was 
about 1/21 of that following oral FK506 
(1 mg/kg). 
Morishita et al. 
2005 
Inhaled TAC (5, 10, 20 puffs 
per day), IM TAC (0.05, 0.1 
or 1.0 mg/kg/day) 
Rat Orthotopic 
Lung 
Transplantation 
Model 
Inhaled TAC enhances acute lung 
allograft survival with lower blood 
concentrations than when using 
comparable intramuscular 
administration. (10 puff/day vs 0.1 
mg/kg/day). Trough concentrations of 
TAC in blood were detectable with 0.1 
mg/kg/day of intramuscular FK 506, but 
not with 10 puffs/day. 
Ingu et al. 2005 
Inhaled TAC (6, 12 puffs  3 
times per day), IM TAC (0.3, 
0.5 or 1.0 mg/kg/day) 
Rat Orthotopic 
Lung 
Transplantation 
Model 
Similar histologic grade of the graft, 
lower blood and allograft concentration, 
less severe weight loss and diarrhea.  
Ide et al. 2007 
Aerosolized TAC gengrated 
by nebulizer for 20min once 
daily (4 mg/kg, dissolved in 
70% ethanol), oral TAC 
(4mg/kg) once daily 
Rat Orthotopic 
Lung 
Transplantation 
Model and in 
vitro cell 
culture 
Similar tracheal tissue level of TAC with 
higher lung-tissue concentrations and 
blood level approximately (5.5-11 times) 
lower, similar histology grade of grafts, 
far less effective in systemic cellular 
immune activation. No airway toxicity, 
decreases more effectively inflammatory 
airway cytokine production, and inhibits 
NFkB activation. 
Schrepfer et al. 
2007 
Deuse et al. 2010 
Nebulized TAC nanoparticle 
dispersions, single dose and 
28 days continous dosing 
Transplanted 
and 
nontransplanted 
rats 
High lung concentration and low blood 
level of TAC, non-toxic, inhaled TAC 
providing therapeutic concentrations 
locally while not be expected to induce 
toxic side effects. 
Watts et al. 2010 
Watts et al. 2011 
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Table B.1 Aerodynamic parameters of TFF TACMAN before and after acoustic mixing. 
 
Samples 
TFF TACMAN (1:1) 
Original 10%, 60s 30%, 60s 50%, 60s 50%,5min 
MMAD (µm) 5.05±0.33 5.49 5.53 6.08 7.37 
GSD (µm) 2.18±0.14 2.09 2.13 2.02 2.01 
FPF (%) 49.4±3.2 45.17 44.97 39.73 31.64 
TFD (%) 96.8±1.0 97.45 97.81 97.98 98.33 
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Table C.1 Aerodynamic parameters of TFF TACMAN (1:1) using three different DPIs, Handihaler®, 
Aerolizer® and Miat® monodose inhaler. 
DPIs Handihaler® Aerolizer® 
Miat monodose 
inhaler® 
Flow Rate (L/min) 51 90 90 
MMAD (µm) 4.52±0.22 2.28±0.19 2.26±0.13 
GSD (µm) 2.03±0.09 2.11±0.13 2.08±0.10 
FPF (%) 54.6±2.2 83.1±1.9 83.3±1.7 
TFD (%) 96.5±1.4 95.0±1.1 94.2±0.7 
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Table C.2 Aerodynamic parameters of TFF TACMAN (1:1) using three different DPIs, Handihaler®, 
Aerolizer® and Miat® monodose inhaler at low, medium and high flow rate that generated by patients 
clinically. 
 
DPIs Handihaler® Aerolizer® Miat® monodose inhaler 
Flow rate (L/min) 20 30 45 60 90 120 60 90 120 
MMAD (um) 8.3 5.5 4.9 4.5 2.3 1.8 4.6 2.3 1.9 
GSD (um) 1.8 2.1 2.1 2.2 2.1 2.0 2.1 2.1 2.0 
FPF (%) 24.5 44.9 51.6 55.6 83.1 87.4 53.5 83.3 88.8 
TED (%) 95.2 94.5 93.2 95.9 95.0 96.8 95.6 94.2 95.2 
All the experiments have been conducted triply, values in the tables are average, RSD was less than 5%. 
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Table E. 1 Residual solvent amount of TFF processed powders immediately after preparation, stored for a 
week in a desiccator at room temperature (25°C, <15% RH) and in a humidity chamber placed in a heated 
oven (40°C, >90%RH). 
 
Samples 
Residual solvent amount (%) 
Initial 25°C, <15% RH 40°C, >90% RH 
Bulk TAC 2.19% 1.60% 
N/A Bulk Lac Mono 5% 4.70% 
Bulk MAN 0% 0% 
TFF TAC only 0% 0% 0% 
TFF TACLAC 1.89% 2.24% 2.62% 
TFF TACMAN 0% 0% 0% 
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Table J.1 Density and thermal properties used to calculated thermal diffusivity (α) for water and ice. 
 
Properties Water Ice 
k (W/mK) 0.6072 2.22 
ρ (g/cm3) 0.9998 0.9162 
Cp (J/gK) 4.200 2.116 
α (m2/s) 0.144×10-6 1.145×10-6 
Average α (m2/s) 0.6445×10-6 
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Figures 
 
Figure 1.1 Model of airways described by Weibel. Reprinted with permission from 
Lee et al. AAPS J 11, 414-423 (2009). 
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Figure 1.2 Schematic illustration of lung physiology at cellular and extra-cellular levels. Reprinted with 
permission from Ungaro et al. J Pharm Pharmacol 64, 1217-1235 (2012). 
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Figure 1.3 The impact of lung diseases on aerosol particle depostion and absorption. 
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Figure 1.4 Computational modeling of the branching network of airways in the human lung. Only 
generations 0 (trachea) to 12 are illustrated. Reprinted with permission from Martonen etal. Adv Eng Softw 
28, 359-364 (1997). 
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Figure 1.5 Dose-normalized PF-00610355 concentration (C)-time profile following the first inhalation dose 
in healthy volunteers (HV), patients with asthma and COPD (chronic obstructive pulmonary disease). 
Reprinted with permission from Diderichsen et al. Clin Pharmacokinet 52, 443-452 (2013). 
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Figure 1.6 Aerosol particles subject to dissolution, absorption and mucociliary clearance spontaneously. 
Reprinted with permission from Edsbacker et al. Pulmonary Pharmacology & Therapeutics 21, 247–258 
(2008). 
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Figure 2.1 Illustration of RBG and nose-only dosing apparatus for rats. 
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Figure 2.2 DSC profiles of (from top to bottom) micronized bulk TAC, micronized bulk MAN, physical 
mixture of micronized TAC and MAN (1:1), TFF TAC only, TFF MAN only and TFF TACMAN (1:1). 
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Figure 2.3 X-ray powder diffraction patterns (from the top to bottom): micronized bulk TAC, micronized 
bulk MAN, physical mixture of micronized TAC and MAN (1:1), TFF TAC only, TFF MAN only and TFF 
TACMAN (1:1). 
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Figure 2.4 Attenuated total reflectance Fourier transform infrared spectroscopy of (from the top to bottom): micronized bulk TAC, micronized bulk 
MAN, physical mixture of micronized TAC and MAN (1:1), TFF TAC only, TFF MAN only and TFF TACMAN (1:1). 
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Figure 2.5 SEM images of micronized TACMAN (a) and TFF TACMAN (b) under different magnification: 
top (2.70KX, scale bar=10 µm) and bottom (25.00KX, scale bar=1 µm). 
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Figure 2.6 Aerodynamic diameter distribution of TFF TACMAN when emitted from a Miat® monodose 
inhaler at a flow rate of 90 L/min. 
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Figure 2.7 TAC concentration in the rat lungs plotted as percentage of initial dose following exposure to 
dry powder aerosols generated from a rotating brush generator. TFF TACMAN (open cycle) and 
Micronized TACMAN (solid square). 
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Figure 2.8 TAC concentration in whole blood following single dose exposure to dry powder aerosols 
generated from a rotating brush generator. TFF TACMAN (open cycle) and Micronized TACMAN (solid 
square). 
  
0.0
20.0
40.0
60.0
80.0
0 5 10 15 20 25
T
A
C
 b
lo
o
d
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
l)
 
Time (h)  
TFF TACMAN
Micronized TACMAN
142 
 
 
 
Figure 2.9 Two compartment model for determination of lung pharmacokinetics parameters. 
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Figure 3.1 Nucleation and growth of particles between frozen ice chips with high cooling rate in thin film 
freezing (TFF) formulation frozen at -140°C (left); with medium cooling rate in TFF formulation frozen at 
-50°C (middle); with low cooling rate in shelf lyophilized formulation (right). Amorphous ice particles are 
represented as white domains and solute precipitate as solid dots or gray regions. Adapted with permission 
from Engstrom et al. Eur J Pharm Biopharm 65 (2007) 149–162. 
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Figure 3.2 DSC of bulk Rhodamine B, bulk mannitol, Physical Mixture of RHOMAN (1:99), TFF 
RHOMAN (-140°C), TFF RHOMAN (-50°C) and shelf lyophilized RHOMAN. 
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Figure 3.3 X-Ray Diffraction of TFF RHO, TFF MAN, TFF RHOMAN (-140°C), TFF RHOMAN (-50°C) 
and shelf lyophilized RHOMAN. 
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Figure 3.4 Aerodynamic properties of TFF RHOMAN (-140°C), TFF RHOMAN (-50°C) and shelf 
lyophilized RHOMAN determined by Next Generation Impactor (NGI) equipped with Miat Monodose 
Inhaler at flow rate of 90 L/min. 
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Figure 3.5 Geometric particle size distribution of aerosolized TFF RHOMAN (-140°C), TFF RHOMAN (-
50°C) and shelf lyophilized RHOMAN powders determined by Sparytac® equipped with Miat Monodose 
Inhaler at flow rate of 90 L/min. 
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Figure 3.6 Nucleation and growth of particles between frozen ice chips with low solid concentration in TFF 
formulations (A); with high solid concentration in TFF formulations. Amorphous ice particles are 
represented as white domains and solute precipitate as solid dots or gray regions. Reprinted with 
permission from Engstrom et al. Eur J Pharm Biopharm 65 (2007) 149–162. 
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Figure 3.7 Aerodynamic properties of TFF RHOMAN prepared at different solid concentrations (0.5%, 1%, 
5% and 10%) determined by Next Generation Impactor (NGI) equipped with Miat Monodose Inhaler at 
flow rate of 90 L/min. 
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Figure 3.8 Geometric particle size distribution of aerosolized TFF powders prepared at different solid 
concentrations (0.5%, 1%, 5% and 10%) determined by Sparytac® equipped with Miat Monodose Inhaler 
at flow rate of 90 L/min. 
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Figure 3.9 Linear regression of the resulting bulk density of TFF powders to initial solid concentrations. 
  
y = 980.65x + 1.6842 
R² = 0.999 
0
20
40
60
80
100
120
0% 2% 4% 6% 8% 10%
B
u
lk
 D
e
n
si
ty
 (
m
g/
cm
3 )
 
Solid Concentration (w/v) 
152 
 
 
 
Figure 3.10 Mechanical testing of TFF RHOMAN prepared at different solid concentrations (0.5%, 1%, 5% 
and 10%) determined by Texture Analyzer. 
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Figure B.1 Acoustic mixer and mixing mechanisms. 
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Figure D.1 DSC of TFF TACLAC stored at 25°C/15%RH at time 0, 1 month, 3 months and 6 months. 
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Figure D.2 DSC of TFF TACLAC stored at 30°C/75%RH at time 0, 1 month, 3 months and 6 months. 
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Figure D.3 DSC of TFF TACMAN stored at 25°C/15%RH at time 0, 1 month, 3 months and 6 months. 
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Figure D.4 DSC of TFF TACLAC stored at 30°C/75%RH at time 0, 1 month, 3 months and 6 months. 
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Figure F. 1 Aerodynamic properties of micronized TACMAN when emitted from a Miat® monodose 
inhaler at a flow rate of 90 L/min. 
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Figure G.1 TAC concentration in the BAL fluid following single dose exposure to dry powder aerosols 
generated from a rotating brush generator. TFF TACMAN (open cycle) and Micronized TACMAN (solid 
square). 
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Figure H. 1 Immersion-force-curve of TFF RHOMAN (1%) determined by texture analyzer using different 
testing probes. 
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Figure I.1 Mechanical testing of TFF RHOMAN (-140°C), TFF RHOMAN (-50°C) and slow shelf frozen 
RHOMAN powders determined by Texture Analyzer. 
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Appendices 
Appendix A: Prior Arts for Inhaled Tacrolimus 
A.1 Purposes 
The objective of this inquiry is to determine the journal history of the active 
pharmaceutical ingredient, Tacrolimus (TAC), and its potential use in pulmonary delivery. 
A.2 Methods 
Journal searches were conducted using the online databases Web of Science 
(Thomson Reuters Web of Knowledge) available from the University of Texas Libraries. 
Keyword used in the search was “inhaled tacrolimus”, references were chosen based on 
relevance.  
A.3 Results 
Table A.1 summarized the journal history of inhaled TAC. The formulations and 
delivery systems, animal models, results, references are demonstrated in the table.  
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Appendix B: Optimization of Fine Particle Fraction (FPF) of TFF TACMAN (1:1) 
by Acoustic Mixing 
B.1 Purposes 
The purpose of this study was to optimize the FPF of TFF TACMAN using acoustic 
mixing to uniformly break down the “large flocs” of TFF processed brittle matrix 
powders prior to cascade impaction testing, which can benefit for aerodynamic properties 
and future handling and packaging of TFF powders. 
B.2 Methods 
TFF TACMAN (1:1) was prepared as described in Section 2.3.2. The lab acoustic 
mixer and mixing schematic were illustrated in Fig.B.1. The two controllable parameters 
on the acoustic mixer are the mixing intensity and mixing time. TFF TACMAN was 
mixed for 60s at 10% intensity, 60s at 30% intensity, 60s at 50% intensity and 300s at 50% 
intensity, respectively. A Next Generation Pharmaceutical Impactor (NGI) was used to 
evaluate the aerodynamic performance of TFF TACMAN after different mixing time and 
intensity. Handihaler® (loaded with size 3 HPMC capsules containing approximately 3 
mg of formulation was secured to the induction port by a silicone adapter. Aerosols were 
generated over 4s at a flow rate of 51 L/min. Prior to actuation, surfaces of collection 
stages were coated with 1% polysorbate 80 in enthanol (v/v) and allowed to completely 
dry. The cut-off size for each stages were calculated to be 8.80, 4.85, 3.06, 1.79, 1.02, 
0.61 and 0.38 µm from stages 1 to 7 and micro-orifice collector (MOC), respectively. 
Following actuation, the deposited powders in the capsule, inhaler, adaptor, induction 
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port, stage 1 to 7 and MOC was collected by rinsing with 10 mL of methanol:water 
(90:10 v/v), which is then quantified by the TAC HPLC method described in Section 
2.3.9. Total emitted dose (TED), mass median aerodynamic diameter (MMAD), 
geometric standard deviation (GSD) and fine particle fraction (FPF) of delivered dose 
were calculated as described in Section 2.3.9. 
B.3 Results 
Aerodynamic parameters of TFF TACMAN after mixing at different mixing time 
and intensity were shown in Table B.1. A decreasing trend of FPF was observed when 
increased the mixing intensity and prolonged the mixing time, correlated with an 
increasing MMAD. The reason can be attributed to the mixing principal illustrated in 
Fig.B.1, which shows a vessel being subjected to a low frequency acoustic field in the 
axial direction resulting in second order bulk motion of the fluid, known as acoustic 
streaming, which in turn causes a multitude of micro-mixing cells throughout the vessel. 
The characteristic mixing lengths for the RAM technology, operating at 60 Hz, is 
nominally 50 microns. The mixing phenomena in solid-solid systems do not rely upon 
acoustic streaming, but upon particle collisions. For the solid-solid mixing, particles in 
the container are excited by collisions with the vessel base and collisions with other 
particles in the container that can result in harmonic vibrations of the vessel with the 
granular material. The particle-particle or particle-wall collisions caused the TFF 
processed matrix particles to collapse instead of breakage. Accordingly impacted the low-
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density, porous and brittle characteristics of the TFF process powders, further hindering 
the aerosolization process of the TFF brittle matrix powders.  
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Appendix C: Determination of Patient and Device Dependence of TFF TACMAN 
(1:1) 
C.1 Purposes 
The objective of this study is to determine the patients and devices dependence of 
TFF processed brittle matrix powders based on their aerodynamic performance. 
C.2 Methods 
TFF TACMAN (1:1) was prepared as described in Section 2.3.2. To evaluate the 
device dependence, three different dry powder inhalers (DPIs) were selected for aerosol 
testing, Handihaler®, Aerolizer® and Miat® monodose inhaler. The flow rate (L/min) 
that can achieve a 4 kPa pressure drop across the device was pre-determined for each DPI 
(Table C.1). Aerosol testing was carried out using a Next Generation Pharmaceutical 
Impactor (NGI) at the pre-determined flow rate for each DPI. A 4L inhalation volume 
was fixed to calculate the inhalation time for different flow rates. For patient dependence 
investigation, three different flow rates were chosen for each DPI, which represented low, 
medium and high flow rate that a patient can generate clinically (Table C.2). Size 3 
HPMC capsules containing approximately 3 mg of formulation was used for all tests. A 
more detailed NGI testing was described in Section 2.3.9 and all the aerodynamic 
parameters (MMAD, GSD, FPF and TED) were calculated as well. 
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C.3 Results 
  As shown in Table C.1, the flow rate used that can achieve 4 kPa pressure drop 
across Handihaler®, Aerolizer® and Miat® monodose inhaler were 51, 90 and 90 L/min, 
respectively. Aerolizer® and Miat® monodose inhaler have similar design, thereby their 
specific resistance are comparable, hence the same flow rate are required to achieve 4 
kPa pressure drop across them. However, the specific resistance of Handihaler® is much 
higher than the other two DPIs; therefore a lower flow rate is needed to achieve the same 
pressure drop across it [1]. Identical aerodynamic parameters are observed for TFF 
TACMAN using Aerolizer® and Miat® monodose inhaler, because they have similar 
design, leading to similar particle de-agglomeration mechanisms upon actuation with the 
same shear and impaction forces. For Handihaler®, device design is different and the low 
flow rate might generate shear and impaction energy for particle de-agglomeration, 
leading to a lower FPF, larger MMAD and GSD compared to the other two DPIs. There’s 
no significant difference in term of TED for all the three DPIs that have been tested, 
probably because the flow rate used in this study was able to shear the TFF TACMAN 
particles apart and form respirable low-density particles that are small enough to exit 
from the punctured holes on the capsule and enter into the impactor. The flow rates 
chosen to represent low, medium and high for Handihaler® were 20, 30 and 45 L/min; 
for Aerolizer® and Miat® monodose inhaler were the same, 60, 90 and 120 L/min [2-4]. 
For all the three DPIs that have been tested, there was a significant increasing trend in 
term of FPF of TFF TACMAN when the flow rate was increased, correlated with a 
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decreasing trend of MMAD (Table C.2). No significant difference was observed in term 
of TED for all the three DPIs and no matter what flow rate was used (around 95%), 
indicating that even with the very low energy input from the device, the brittle nature of 
TFF processed powders make it possible to emit more than 90% of the TFF powders. In 
summary, the aerodynamic performance of TFF processed powders is dependent of the 
selected DPI device and patients’ inspiratory flow rate. 
C.4 References 
[1] S.L. Lee, W.P. Adams, B.V. Li, D.P. Conner, B.A. Chowdhury, L.X. Yu, In vitro 
considerations to support bioequivalence of locally acting drugs in dry powder inhalers 
for lung diseases, AAPS J, 11 (2009) 414-423. 
[2] SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder), Academy of 
Managed Care Pharmacy (AMCP), Formulary Dossier. 
[3] D.J. Ball, P.H. Hirst, S.P. Newman, B. Sonet, B. Streel, F. Vanderbist, Deposition and 
pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder 
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Appendix D: Physical Stability of TFF processed powders 
D.1 Purposes 
The purpose of this study was to assess the physical stability of TFF TACLAC (1:1) 
and TFF TACMAN (1:1) over time storage at room temperature in a dessicator and 
accelerated temperature and relative humidity (RH). 
D.2 Methods 
The TFF processed powders, TFF TACLAC (1:1) and TFF TACMAN (1:1), were 
stored in a vacuum desiccator (25°C /15%RH) at room temperature and in a humidity 
chamber placed in a heated oven (30°C/75% RH), respectively. Crystallinity was 
evaluated by DSC (30 to 250 °C, ramp rate: 10 °C/min, modulation temperature 
amplitude: 1°C/60 s, nitrogen gas purge flow rate: 40 mL/min) at time 0, 1 month, 3 
months and 6 months.  
D.3 Results 
For physical mixture of TACLAC (Fig.D.1 and D.2), TAC melts around 127°C; the 
endothermic peak around 146°C is the crystal water in the lactose molecule lattice and 
the melting peak of LAC is around 210°C. TFF TACLAC exhibited a Tg of TAC around 
75 °C and recrystallization peak and the melting peak corresponding to LAC, no melting 
of TAC was detected indicating that both TAC and LAC are amorphous. When stored at 
room temperature and less than 15% RH in a desicctor, no significant change in terms of 
thermal properties was observed (Fig.D.1), indicating that TAC and LAC are still 
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amorphous up to 6 months storage at 25°C /15%RH. However, when TFF TACLAC was 
stored at accelerated condition (30°C/75% RH), TAC and LAC started to crystallize 
around 127°C and 210°C, respectively. Moisture was absorbed into the crystal lattice of 
LAC, showing an endothermic peak around 147°C. After 6 months storage, the melting 
peak of TAC and this crystal water peak combined to a broader peak at 137°C (Fig.D.2). 
No recrystallization peaks and no glass transition temperature were detected upon storage, 
indicating that TAC and LAC were no longer amorphous. For TACMAN (Fig.D.3), TAC 
and MAN melt at 127°C and 169°C, respectively. TFF TACMAN exhibited a Tg around 
75°C, corresponding to TAC; MAN only displayed a melting peak, indicating that TAC 
is amorphous and MAN is crystalline in TFF TACMAN. Whether stored at 25°C 
/15%RH or 30°C/75% RH, no significant change was observed in the DSC profiles, 
meaning that TFF TACMAN was robust to moisture. To sum up, TFF TACMAN is 
physically more stable than TFF TACLAC.   
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Appendix E: Residual Solvent Analysis of TFF-processed Powders by 
Thermogravimetric Analysis (TGA) 
E.1 Purposes 
The objective of this study was to determine the amount of the residual solvent in the 
TFF processed powders stored at room temperature in a desiccator and at accelerated 
conditions. 
E.2 Methods 
Three TFF processed powders were subjected to TGA testing, TFF TAC only, TFF 
TACLAC and TFF TACMAN. They were prepared by using a co-solvent system 
containing acetonitrile (CAN) and water (60:40, v/v) and the detailed description can be 
found in Section 2.3.2. After prepared, TFF processed powders were stored for a week in 
a desiccator at room temperature (25°C, <15% RH) and in a humidity chamber placed in 
a heated oven (40°C, >90%RH). Then residual solvent content was determined using a 
Mettler-Toledo TGA/DSC 1. TFF-processed powders and their individual components were 
accurately weighed to 10-15 mg into 100 μL aluminum pans. The samples were ramped from 
25 to 180°C at 10°C/minute then held at 180°C for 30 minutes. The difference between the 
final sample weight and the initial sample weight was used to calculate the percentage of 
residual solvent lost on drying.  
E.3 Results 
As shown in Table E.1, bulk TAC and bulk LAC were both monohydrate forms, 
therefore the theoretical water amount in them are 2.19% and 5%, respectively. The 
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measured water amount of bulk TAC and bulk LAC were 1.6% and 4.7%. It has been 
reported by Watts et al. that no detectable amount of ACN was measured in 50 mg of 
TFF processed powders [1]; therefore, we can assume that the measured residual solvent 
by TGA is mainly water. Because of the hydrophobic nature of TAC molecules, TFF 
TAC only did not absorb any moisture immediately after preparation, or stored after a 
week under two different conditions. For TFF TACLAC, immediately after preparation, 
the residual solvent was 1.89%; upon storage in a desiccator at room temperature (25°C, 
<15% RH), the residual solvent increased to 2.24%; when stored in accelerated condition 
(40°C, >90%RH), the residual solvent amount increased to 2.62%. Because of the 
amorphous nature of LAC in TFF TACLAC, it tends to absorb moisture upon storage. 
For TFF TACMAN, the residual solvent remained at 0% for a week no matter what 
storage conditions was used. In TFF TACMAN, TAC is hydrophobic and MAN is 
crystalline, which attributes to the robust characteristic to moisture. 
E.4 References 
[1] A.B. Watts, J.I. Peters, R.L. Talbert, K.P. O'Donnell, J.J. Coalson, R.O. Williams, 3rd, 
Preclinical evaluation of tacrolimus colloidal dispersion for inhalation, Eur J Pharm 
Biopharm, 77 (2011) 207-215. 
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Appendix F: Aerodynamic properties of micronized TACMAN (1:1) 
F.1 Purposes 
This appendix is intended to supplement the study conducted in Chapter 2 Section 
2.3.9. The objective is to determine the aerodynamic properties of micronized TACMAN 
(1:1).  
F.2 Methods 
Micronized TACMAN (1:1) was prepared according to the description in Section 
2.3.2. The aerodynamic properties of micronized TACMAN were investigated by a NGI 
similar to the set up for testing TFF TACMAN in Section 2.3.9.  Miat monodose 
inhaler® loaded with size 3 HPMC capsules containing approximately 3 mg of 
micronized TACMAN was secured to the induction port by a silicone adapter. Aerosols 
were generated over 2.7 s at a flow rate of 90 L/min to achieve an inhalation volume of 4 
L. Prior to actuation, surfaces of collection stages were coated with 1% polysorbate 80 in 
enthanol (v/v) and allowed to completely dry. Following actuation, the deposited 
powders in the capsule, inhaler, adaptor, induction port, stage 1 to 7 and MOC was 
collected by rinsing with 10 mL of methanol:water (90:10 v/v) and subjected to TAC 
quantification (Section 2.3.9). Aerodynamic parameters were calculated according to the 
description in Section 2.3.9 as well. 
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F.3 Results 
As demonstrated in Fig.F.1, micronized TACMAN (1:1) exhibited excellent 
aerodynamic properties when actuated from a commercially available DPI. The FPF of 
emitted dose of micronized TACMAN reached up to 88.5%, the MMAD and GSD of 
micronized TACMAN were 1.55 and 2.07 µm, respectively and the TED was 72.6%.   
Appendix G: Determination of Tacrolimus Concentrations in the Bronchoalveolar 
Lavage (BAL) Fluid  
G.1 Purposes 
This appendix is designated to supplement the study conducted in Section 2.3.10. 
The purpose is to measure the TAC concentrations in BAL fluid and assist in 
pharmacokinetic analysis. 
G.2 Methods 
Rats BAL fluid was collected as described in Section 2.3.10. Briefly, the trachea 
was exposed by blunt dissection of the sternohyoideus muscle and a small incision in the 
middle was made to insert the lavage needle outfitted with a 5 mL BD syringe. 
Approximately 3 mL of sterile phosphate buffered saline (PBS) was slowly injected to 
fill the lungs and the BAL fluid was withdrawn by gentle aspiration. This procedure was 
conducted twice so the total yield of BAL was between 4-5 mL. Then the BAL fluid was 
stored in a -80°C freezer prior to analysis. TAC was quantified in BAL fluid according to 
the following protocol.   Briefly, 100 µL of calibrator, control, and unknown samples 
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were mixed by vortexing with 10 µL of 0.5 µg/mL Ascomycin (ASCO, internal standard) 
and 200 µL of a solution containing 0.1% formic acid and 10 mM ammonium formate 
dissolved in 95% HPLC grade methanol for 2 min.  After vortexing the samples were 
transferred to 1.5 ml microfilterfuge tubes and then centrifuged at 15,000 g for 1 min at 
23
o
C.  Filtrates were transferred to autosampler tubes and 40 µL of the final extracts were 
injected into the LC/MS/MS (same system used in Section 2.3.11).  The ratio of the peak 
area of TAC to that of the internal standard ASCO (response ratio) for each unknown 
sample was compared against a linear regression of calibrator response ratios at 0, 1, 2.5, 
10, 20, 40 and 160 ng/mL to quantify TAC.  The concentration of TAC was expressed as 
ng/mL in BAL fluid. 
G.3 Results 
As shown in Fig.G.1, TAC concentrations in the BAL fluid of TFF TACMAN were 
higher than that of micronized TACMAN. The reason can be attributed to the faster 
dissolution rate of amorphous TFF TACMAN, compared to crystalline micronized 
TACMAN [1, 2]. For amorphous TFF TACMAN, the rapidly dissolved TAC molecules 
immediately became available for absorption into either the lung tissue or the systemic 
blood circulation. It has been reported by Patton et al. that hydrophobic small molecules 
can be absorbed into the blood stream extremely fast, approximately 1 to 2 minutes [3]. 
In this study, once TAC is dissolved in lung lining fluid, the absorption into the lung 
tissue and blood circulation is pretty fast. For crystalline micronized TACMAN, the slow 
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dissolving TAC particles acted as a reservoir and continuously released TAC molecules 
into the lung lining fluid, leading to a higher TAC concentrations in the BAL fluid.  
G.4 References 
[1] P. Sinswat, K.A. Overhoff, J.T. McConville, K.P. Johnston, R.O. Williams, 3rd, 
Nebulization of nanoparticulate amorphous or crystalline tacrolimus--single-dose 
pharmacokinetics study in mice, Eur J Pharm Biopharm, 69 (2008) 1057-1066. 
[2] A.B. Watts, J.I. Peters, R.L. Talbert, K.P. O'Donnell, J.J. Coalson, R.O. Williams, 3rd, 
Preclinical evaluation of tacrolimus colloidal dispersion for inhalation, Eur J Pharm 
Biopharm, 77 (2011) 207-215. 
[3] J.S. Patton, C.S. Fishburn, J.G. Weers, The Lungs as a Portal of Entry for Systemic 
Drug Delivery, Proc Am Thorac Soc, 1 (2004) 338-344. 
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Appendix H: Mechanical Testing of TFF Processed Powders by Texture Analyzer 
using Different Selection of Probes 
H.1 Purposes 
The objective of this appendix is to select the appropriate probe to carry out 
mechanical testing for TFF processed powders by texture analyzer. 
H.2 Methods 
TFF RHOMAN (1% solid concentration) was prepared as described in Section 3.3.2 
and used for the test. The mechanical properties of TFF processed powders were 
evaluated using a Texture Analyzer (TA.XT.plus, Stable micro Systems, Godalming, 
United Kingdom) equipped with a 5 kg load cell. Three different probes were used in the 
study, a 1/4 inch sphere probe, a 7 mm flat probe and a 10 mm stainless steel probe. Test 
was conducted at a speed of 1 mm/s and a maximal immersion into the bulk powders of 
20 mm. Compression mode was applied in the test. The probe compressed the bulk 
powders by proceeding at constant speed and the force needed for the immersion was 
recorded. The resulting immersion force represents the force requires for breakage of 
TFF processed powders. At the end of the immersion, the probe returned to its original 
height. 
H.3 Results 
As shown in Fig.H.1, when immersed into the 1% TFF RHOMAN at the same depth, 
the 10 mm flat probe detected greater immersion forces than the 7 mm flat probe and the 
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1/4 inch sphere probe sensed the smallest immersion forces due to their surface 
differences when contacting with the bulk powders. Therefore, the 10 mm flat probe is 
the most sensitive probe and will be used for future mechanical testing of TFF processed 
powders.  
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Appendix I: Mechanical Testing of TFF Processed Powders Prepared at Different 
Freezing Rates by Texture Analyzer 
I.1 Purposes 
The aim of this study is to evaluate the mechanical properties of TFF processed 
powders prepared at different freezing rates.  
I.2 Methods 
As described in Section 3.3.2, a solution of RHO and MAN (1:99 w/w, solid 
concentration:1% w/v) was rapidly frozen on a on a cryogenically cooled rotating 
stainless steel surface (−50°C or -140°C). The resulting thin film was removed from the 
surface by a scraper and maintained in the frozen state in liquid nitrogen. Solvents were 
sublimated by lyophilization over 48 hours at pressures less than 200mTorr while the 
shelf temperature was gradually ramped from −40°C to 25°C. For the slow shelf freezing 
RHOMAN, solution of RHO and MAN was slowly frozen in a freezer (-80°C) and then 
subject to lyophilization. The mechanical properties of TFF processed powders prepared 
at different freezing rate were evaluated using a Texture Analyzer equipped with a 5 kg 
load cell and a 10 mm cylindrical probe. Test was conducted at a speed of 1 mm/s and a 
maximal immersion into the bulk powders of 10 mm. Compression mode was applied in 
the test. The probe compressed the bulk powders by proceeding at constant speed and the 
force needed for the immersion was recorded. The resulting immersion force represents 
the force requires for breakage of TFF processed powders. 
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I.3 Results 
As illustrated in Fig.I.1, by immersing 10 mm in the bulk powders, none of the 
formulations exhibited immersion forces greater than 0.01 N. No significant difference in 
term of positive area under the curve was observed for the three formulations prepared by 
different freezing processes, indicating that there’s no significant difference in term of 
mechanical properties between formulations prepared by different freezing process. 
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Appendix J: Theoretical Modeling of the Freezing Rate of Formulations Prepared 
by Different Freezing Processes 
J.1Purposes 
The objective this appendix is to calculate the freezing rate of formulations prepared 
by different freezing processes according to theoretical modeling. 
J.2 Methods 
Three different freezing processes were applied to a solution of RHO and MAN 
(1:99, w/w) in water (1%, w/v). TFF process with cryogenic surface temperature at 
−50°C, -140°C and a slow freezing on the shelf (-40°C) process. Following the freezing 
process, solvent was sublimated by lyophilization over 48 hours at pressures less than 
200mTorr while the shelf temperature was gradually ramped from −40°C to 25°C. 
Calculation of the freezing rate was based on the theoretical model reported by Overhoff 
et al. and Engstrom et al. [1, 2].   
J.3 Results 
The phenomena of droplet spreading and freezing upon impinging with a cryogenic 
solid substrate have been previously studied [1, 2]. The fact of whether the droplet will 
first spread or solidify to form thin films upon impact with the cryogenic surface has been 
described in terms of the Weber number, We=ρV2D/γ (inertial to interfacial forces) 
where ρ is the liquid droplet density; V is the impact velocity; D is the droplet diameter 
and γ is the droplet interfacial tension in air. For We>30, droplets spread immediately 
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upon impacting the cryogenic solid substrate and deformed into cylindrical thin films 
before solidifying; for low We<1, impacting droplets solidified as spherical domes with 
minimal spreading [3-6]. In this study, water was used as a solvent in the TFF process, γ 
(air–water) =0.072 N/m; droplets were falling from a height of 10 cm, V= (2gH) 1/2 
=1.414 m/s; ρ=1000 kg/m3 for water droplets; the volume of the water droplet was 
determined by dropping 20 droplets into a graduated cylinder to measure the volume (the 
volume of 20 droplets was about 1.6 mL, thereby the volume of one drop is 
approximately 0.08 mL) and the diameter D =2(3Volume/4π) 1/3 =0.0053 m. Therefore, 
the calculated We= 147, which is >30, and means that the water droplets will spread on 
the surface and deform into cylindrical thin films prior to being frozen. This correlated 
with the observed formation of thin cylindrical disks. 
The diameter of the frozen cylindrical disks were measured across two directions and 
averaged for 10 droplets. The thickness of the frozen cylindrical disks was then 
calculated by assuming that a droplet impacting on the cryogenic substrate will deform 
into a cylindrical disk with the same volume as the original droplet. In this study, no 
significant difference was observed for the diameter of the frozen cylindrical disks 
between the two TFF formulations prepared at different freezing temperatures (-50°C and 
-140°C). The measured diameters for both TFF formulations were 12 mm. It has been 
reported by Fukai et al. that the diameter of the thin films depends on the Weber number 
and the surface temperature of the cryogenic substrate, and the diameter increases as the 
Weber number increases [3]. On a stainless steel surface, for a relatively large Weber 
number (200-600), higher surface temperature (523 K) results in larger diameters of the 
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thin films (usually ranging from 4-6 times the original droplet diameter), compared to the 
diameters (usually ranging from 3-4 times the original droplet diameter) resulting from a 
lower surface temperature (300 K); For an intermediate Weber number (30-200), the 
diameter of the resulting thin films typically ranges from 1.5-3 times the original droplet 
diameter and the surface temperature does not significantly impact the diameter; for a 
small Weber number (<30), no deformation is expected to occur and the droplets are 
frozen as spherical domes with minimal spreading [3]. In this study, the Weber number 
was 147 and the measured diameter of the thin films (12mm) is approximately 2.3 times 
the original droplet diameter (5.3mm). Therefore, the surface temperature difference did 
not impact the resulting diameter of the frozen cylindrical disks. The thickness of the 
frozen disks was calculated to be 176.8 µm for both TFF formulations.  
It was previously demonstrated with infrared imaging of cooling thin films that the 
water droplets’ spreading occurred within the first 10 milliseconds upon impact with the 
cryogenic surface, which is much shorter than the freezing time (hundred to thousand 
milliseconds) [2]. The cooling rate of the thin films can be predicted with a simplified 
analytical heat transfer model, which was validated with experimental IR data [1]. Briefly, 
a few assumptions are made based on the theoretical model. The first assumption is that 
the spreading of water droplets happens in a very short time scale compared to the 
freezing time so no heat transfer occurs during the spreading process. The second 
assumption is that since the thickness of the thin films was relatively small (176.8 µm) 
compared to its large diameter (12mm), heat transfer only occurs in the z-direction and 
the heat transfer paralleled to the surface is negligible. The last assumption is that the 
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thermal diffusivity, α=k/ρ×Cp (where k is the thermal conductivity, ρ is the density, and 
Cp is the heat capacity) is constant over the entire temperature range and stays unchanged 
during the freezing process. For the case of freezing water the density and thermal 
properties were determined from the DIPPR database (Brigham Young University, Provo, 
UT) at the initial temperatures of 298 and 273K for water and ice, respectively (Table 
J.1). The average thermal diffusivity of water and ice was used for the mathematical 
model. Two boundary conditions were fit into the model, the air is acted as an insulator 
so the heat transfer from the top surface of the thin film to the exposed air is negligible; 
the cryogenic surface temperature remains constant so there is no heat transfer resistance 
between the cryogenic substrate and the water droplets. Therefore, a one-dimensional 
heat transfer for a finite slab according to the two boundary conditions above is described 
by the following equation: 
 (   )       
 
 
 
∑    (    )
        
 
   
    
(    )  
  
{
  (  )        
(    ) 
 ∫   
   (    )   
  
   
 
 
} 
where x is the distance from the top of the spread droplet, T(x,t) is the temperature in 
the film reaching distance x and at time t, Tcryo is the temperature of the cryogenic 
substrate in contact with the bottom thin film surface, and L is the film thickness [7]. 
Then the cooling time (ms) was calculated by determining the time t, it takes for the top 
surface of the thin film at x=0 with thickness L to reach a given temperature T (freezing 
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point of water, 273.15K). The cooling rate (K/s) was determined by dividing the 
temperature change at the top surface of the thin film (from room temperature to freezing 
point of water) by the cooling time. As shown in Table 1, the calculated cooling time for 
TFF process at -140°C and -50°C were 106ms (cooling rate 2.36×10
2
 K/s) and 148ms 
(cooling rate 1.69×10
2
 K/s), respectively. For the sample frozen directly on the tray of the 
lyophilizer, the observed cooling time was more than 10
6
ms with a very slow cooling rate 
(<2.5×10
-5
 K/s). 
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